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Abstract
Humane care for critically ill pediatric patients supported on mechanical ventilation necessitates comfort
management that includes sedation therapy. Critically ill patients quickly become tolerant to the opioids and
benzodiazepines used for sedation therapy and require increasing doses of these medications to achieve the
same therapeutic effect. In turn, after recovery from their primary illnesses, rapid weaning or abrupt cessation
of sedative therapy in drug tolerant patients precipitates iatrogenic withdrawal syndrome - a problem that adds
to the personal and financial burden of intensive care. While numerous studies have focused on illuminating
iatrogenic withdrawal syndrome symptomatology, a new perspective for addressing this preventable
complication of pediatric intensive care is now warranted. This dissertation will use data from the RESTORE
clinical trial [U01HL086622 and U01HL086649 (PI: Curley & Wypij); 31-center cluster randomized trial of
nurse-led sedation management on clinical outcomes in children requiring mechanical ventilation for acute
respiratory failure] to conduct a series of analyses comparing patient-, process- and system-level data between
those subjects who developed iatrogenic withdrawal syndrome and those who did not. By exploring variables
at multiple levels, this study will be the most comprehensive evaluation of iatrogenic withdrawal syndrome
ever completed and will contribute new knowledge to the field. The studies will collectively answer the key
question: What factors impact the development of iatrogenic withdrawal syndrome in pediatric patients
recovering from critical illness? Furthermore, the relative contributions of patient, process, and systems
factors will be combined to create a predictive model of patient risk for clinically significant iatrogenic
withdrawal syndrome in pediatric patients recovering from critical illness. This dissertation will contextualize
the phenomenon of iatrogenic withdrawal syndrome within the unique clinical circumstances in which it
occurs. More importantly, risk factors identified through this study could lead to the development of
personalized risk profiles and prevention protocols for vulnerable children in the pediatric intensive care unit.
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ABSTRACT 
 
DEFINING RISK FOR IATROGENIC WITHDRAWAL IN  
CRITICALLY ILL CHILDREN 
Kaitlin M. Best 
Martha A. Q. Curley 
Humane care for critically ill pediatric patients supported on mechanical ventilation 
necessitates comfort management that includes sedation therapy. Critically ill patients 
quickly become tolerant to the opioids and benzodiazepines used for sedation therapy and 
require increasing doses of these medications to achieve the same therapeutic effect. In 
turn, after recovery from their primary illnesses, rapid weaning or abrupt cessation of 
sedative therapy in drug tolerant patients precipitates iatrogenic withdrawal syndrome - a 
problem that adds to the personal and financial burden of intensive care. While numerous 
studies have focused on illuminating iatrogenic withdrawal syndrome symptomatology, a 
new perspective for addressing this preventable complication of pediatric intensive care 
is now warranted. This dissertation will use data from the RESTORE clinical trial 
[U01HL086622 and U01 HL086649 (PI: Curley & Wypij); 31-center cluster randomized 
trial of nurse-led sedation management on clinical outcomes in children requiring 
mechanical ventilation for acute respiratory failure] to conduct a series of analyses 
comparing patient-, process- and system-level data between those subjects who 
developed iatrogenic withdrawal syndrome and those who did not. By exploring variables 
at multiple levels, this study will be the most comprehensive evaluation of iatrogenic 
withdrawal syndrome ever completed and will contribute new knowledge to the field. 
vi 
The studies will collectively answer the key question: What factors impact the 
development of iatrogenic withdrawal syndrome in pediatric patients recovering from 
critical illness? Furthermore, the relative contributions of patient, process, and systems 
factors will be combined to create a predictive model of patient risk for clinically 
significant iatrogenic withdrawal syndrome in pediatric patients recovering from critical 
illness. This dissertation will contextualize the phenomenon of iatrogenic withdrawal 
syndrome within the unique clinical circumstances in which it occurs. More importantly, 
risk factors identified through this study could lead to the development of personalized 
risk profiles and prevention protocols for vulnerable children in the pediatric intensive 
care unit. 
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CHAPTER 1 
INTRODUCTION 
 The rapid evolution of pediatric intensive care over the past 40 years has been 
accompanied by fundamental changes in comfort management for critically ill children. 
Comfort care in critically ill, non-surgical pediatric patients supported on mechanical 
ventilation relies primarily on the use of opioids and benzodiazepines for sedation. However, 
tolerance to and physical dependence on the opioids and benzodiazepines used for 
sedation therapy can develop within a short span of time (Anand et al., 2010; Barr, 
McPhie-Lalmansingh, Perez, & Riley, 2011; Jenkins, 2011). During recovery from their 
primary illnesses, failure to gradually wean sedative therapy in physically dependent 
patients leads to iatrogenic withdrawal syndrome (IWS), a cluster of physiologic signs 
and symptoms that includes elevated temperature, tachycardia and hypertension, 
protracted vomiting, severe diarrhea, and seizures (Franck, Harris, Soetenga, Amling, & 
Curley, 2008; Franck, Scoppettuolo, Wypij, & Curley, 2012). Despite this known 
complication of sedation therapy, opioids and benzodiazepines are an essential 
pharmacologic therapy in the pediatric intensive care unit (PICU); therefore, this 
dissertation study explores risk factors for IWS in critically ill children, in order to further 
our understanding of which children are at greatest risk for experiencing this 
phenomenon and arm clinicians with knowledge on how best to prevent IWS.  
This chapter will provide important background information regarding the clinical 
circumstances in which critically ill children receive PICU care and experience the use of 
sedative and analgesic medications, in order to provide a more complete understanding of 
the context in which the phenomenon of IWS occurs. Subsequent chapters will present 
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the three component papers that comprise this dissertation study: First, a systematic 
review of the available literature was undertaken in order to identify known risk factors 
for IWS (Chapter 2). Established and hypothesized risk factors were incorporated into a 
conceptual model that guided subsequent data analyses. The remaining sections of this 
dissertation study used data from the Randomized Evaluation of Sedation Titration fOr 
Respiratory FailurE (RESTORE) study (U01HL086622 and U01 HL086649; PIs: Curley 
& Wypij), a 31-center cluster randomized trial investigating the effects of a nurse-led, 
goal-directed sedation management protocol on clinical outcomes in children requiring 
mechanical ventilation for acute respiratory failure in the PICU.  
Given the key role that the rate of sedation weaning plays in the incidence of 
IWS, the second component of this study analyzed current patterns of weaning from 
sedative medications in usual practice, using data from 308 subjects enrolled during the 
baseline, pre-randomization phase of the RESTORE trial (Chapter 3). The findings from 
that analysis helped elucidate the relationships among tolerance, weaning, and IWS. 
Specifically, analysis of the baseline population allowed development, testing and 
refinement of operational definitions for tolerance and weaning that were under 
developed in the literature on IWS in the PICU; those definitions and identified 
relationships between tolerance and pattern of weaning offered important insights 
affecting the incorporation of those variables in later analyses.  
Finally, a secondary analysis of existing data from the 2449 subjects enrolled 
during the intervention phase of the RESTORE trial was conducted, in order to identify 
statistically significant risk factors associated with the outcome of IWS (Chapter 4). By 
3 
exploring variables at several levels, this study is one of the most comprehensive 
evaluations of IWS to date.  
	   The specific aims for this dissertation were as follows:  
1. To identify risk factors for clinically significant IWS in pediatric patients 
recovering from critical illness. (CHAPTER 2) 
2. To characterize patterns of weaning from opioids and/or benzodiazepines in 
pediatric patients recovering from critical illness, as they relate to the outcome of 
clinically significant IWS. (CHAPTER 3) 
3. To create a predictive model of patient risk for clinically significant IWS in 
pediatric patients recovering from critical illness, based on the relative 
contributions of patient, process, and systems factors. (CHAPTER 4) 
The following sections provide a comprehensive discussion of the population of patients 
who require sedation in the PICU, the context in which sedative medications are 
administered, and how these factors contribute to the development of IWS. The 
biological mechanisms underlying the development of tolerance, physical dependence 
and subsequent IWS are described. In addition, current clinical practices in assessing for 
and managing IWS are reviewed.  This information provides the necessary baseline 
knowledge upon which the three studies in the remainder of the dissertation were built. 
Background 
Nearly 150,000 critically ill infants and children in the United States are 
supported on invasive mechanical ventilation in the PICU every year (Agency for 
Healthcare Quality and Research, 2009). Various ventilator modes have been developed 
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to attempt to match ventilator-delivered breaths with the child’s spontaneous efforts, but 
patient-ventilator asynchrony still develops and can be a source of significant discomfort 
(Cheifetz, 2003).  Humane care for these patients necessitates comfort management, a 
multi-dimensional concept that addresses issues of pain, agitation, anxiety, and insomnia. 
Approaches to care include both non-pharmacologic and pharmacologic interventions to 
increase patient comfort (Anand & the International Evidence-Based Group for Neonatal 
Pain, 2001; Herr et al., 2006).  Because of the diversity of pharmacologic agents available 
for comfort management, by the time the first consensus guideline on sedation 
management in critically ill children was released in the United Kingdom in 2006, 
(Stephen Playfor et al., 2006) up to 24 different medications were being used in PICUs 
worldwide for analgesia and sedation to facilitate mechanical ventilation (Jenkins, 
Playfor, Bevan, Davies, & Wolf, 2007; Twite, Rashid, Zuk, & Friesen, 2004; Vet et al., 
2013). 
Combination therapy, including an opioid and a benzodiazepine, is the most 
common strategy for sedation of patients in the PICU (Ista, van Dijk, Gamel, Tibboel, & 
de Hoog, 2008; Jenkins et al., 2007; Vet et al., 2013). The recommended and most 
commonly used medications are morphine, fentanyl and midazolam (Jenkins et al., 2007; 
Lasky, Ernst, & Greenspan, 2012; Twite et al., 2004). Continuous infusions of opioids, 
including morphine and fentanyl, have rapid analgesic effects that are useful in reducing 
discomfort associated with mechanical ventilation, while also helping to prevent 
ventilator asynchrony and working synergistically with benzodiazepines to promote 
sedation (Johnson, Miller, & Hagemann, 2012). Benzodiazepines are highly effective  
 
5 
sedatives and anxiolytics, and their amnestic effects are also valued in the PICU, where 
memories of mechanical ventilation and invasive procedures can have significant, long-
term negative psychological effects (Colville, Kerry, & Pierce, 2008; Colville, 2008; 
Rennick & Rashotte, 2009; Rennick et al., 2004). 
Context of Sedation Management in the PICU  
Sedation for mechanical ventilation in the PICU takes place within a unique 
context, whose characteristics both directly and indirectly impact the effectiveness of the 
therapies that are delivered. A number of factors have been found to influence nurses’ 
provision of sedation therapy in the adult ICU literature, including: lack of standing 
physician orders, lack of acceptance for sedation protocols (Tanios, de Wit, Epstein, & 
Devlin, 2009), nurses’ knowledge and attitudes, and perceived autonomy in managing 
sedative administration (Guttormson, Chlan, Weinert, & Savik, 2010). These findings can 
reasonably be extrapolated to the population of pediatric critical care nurses. Other 
literature has shown that nurses’ level of education and clinical experience (Aiken, 
Clarke, Cheung, Sloane, & Silber, 2003; Coffman et al., 1997; Kutney-Lee, Sloane, & 
Aiken, 2013) influence their ability to manage patient complications and provide comfort 
care during acute illness. Less experienced nurses are more likely to administer sedatives, 
preferring more sedated patients (Egerod, 2002; Guttormson et al., 2010). By contrast, 
more experienced nurses feel more confident in titrating sedation to patient condition 
(Walker & Gillen, 2006; Weir & O’Neill, 2008). However, research on workarounds, or 
behaviors employed by nurses to bypass perceived obstructions in their workflow, has 
shown that greater seniority and expertise in critical care may make nurses more likely to 
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deviate from standard protocols that they consider to be unimportant or not useful 
(Debono et al., 2013).  Observed differences in adherence to sedation management 
protocols across clinician groups (Burns 2012; Ista, de Hoog, Tibboel & van Dijk, 2009; 
Weir & O’Neill, 2008) suggest that nurses are susceptible to developing professionally 
cultivated attitudes toward the care of children requiring sedation, which in turn impact 
their management of patients.  
Pediatric critical care nurses function within a team of providers. The teamwork 
required by PICU care necessitates interaction among multiple providers who may bring 
varying perspectives and levels of knowledge or skill to the management of pediatric 
sedation (Schechter, Berde, & Yaster, 2003; E. J. Thomas, Sexton, & Helmreich, 2003). 
The knowledge base surrounding sedation management is currently divided across 
numerous fields (Schechter et al., 2003). Research has attempted to ensure consistent 
communication across disciplines regarding sedation through the use of objective 
measurement scales, such as the State Behavioral Scale (SBS) (Curley, Harris, Fraser, 
Johnson, & Arnold, 2006) and the Withdrawal Assessment Tool-version 1 (WAT-1) 
(Franck et al., 2008; Franck et al., 2012). But these assessment tools have not yet been 
fully integrated in practice (Larson, Arnup, Clifford, & Evans, 2013) and are not 
thoroughly embedded in clinical decision-making. This may be because nurses have 
reported using both their clinical judgment and assessment tools together (Walker & 
Gillen, 2006) or a result of inconsistent use of these tools among members of the clinical 
team (Weir & O’Neill, 2008).  
Lack of interprofessional collaboration and nurse autonomy (Olmstead, Scott, &  
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Austin, 2010; Schechter et al., 2003; E. J. Thomas et al., 2003) may complicate the 
process of providing sedation therapy in the PICU. One survey found that only 55% of 
nurses felt that nurses and physicians communicated clearly regarding sedation goals 
(Walker & Gillen, 2006). Nurses attempting to implement sedation protocols may be 
frustrated by other providers’ lack of adherence (Weir & O’Neill, 2008), which may 
serve to decrease their apparent or actual protocol compliance. For example, in a recent 
study of nurses’ satisfaction with using the WAT-1 for patient assessment, 90% of nurses 
reported that the WAT-1 was a helpful tool in their practice but they also cited a lack of 
physician willingness to change the patient’s weaning plan on the basis of assessment 
findings (Suddaby & Josephson, 2013). This reluctance persisted despite reported 
improvements in communication about sedation and weaning with the implementation of 
withdrawal assessments.   
Nurses caring for children requiring sedation operate within high-volume units, 
which may struggle with low nurse-to-patient ratios or insufficient staffing, both of which 
have been shown to increase the risk of iatrogenic patient complications (Carayon & 
Gürses, 2005; Tubbs-Cooley, Cimiotti, Silber, Sloane, & Aiken, 2013). Specifically with 
regard to sedation and analgesia management, unit volume and staffing have been found 
to have a complex relationship with protocol or guideline implementation and adherence: 
standard protocols may be more likely to be used in larger units (i.e., ≥20 beds), (Tanios, 
de Wit, Epstein, & Devlin, 2009; Gharavi et al., 2007), but the effect of written 
guidelines on increasing attention to sedation and analgesia may only last until the point 
at which high unit volumes and poor staffing serve to decrease compliance (Slomka et al.,  
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2000).  In contrast, the literature on nursing workforce issues has highlighted Magnet-
designated hospitals as excellent work environments, with improved nurse and patient 
outcomes (McHugh et al., 2013). The potential impact of nurse staffing, workloads, and 
work environments, including the influence of working in a Magnet versus non-Magnet 
institution on patient outcomes on sedation for mechanical ventilation, remains 
unexplored.  
Achieving an optimal level of sedation – that is, one that makes a child safe and 
comfortable during the course of their mechanical ventilation using the lowest amount of 
sedation possible – is a key objective of comfort management in the PICU (Johnson et 
al., 2012; Playfor et al., 2006). However, adequately sedating critically ill children 
remains an elusive goal in practice: a recent review of sedation assessments in PICUs 
around the world found that up to 32% of patients are over-sedated and 11% are under-
sedated after pooling observations from a variety of different assessment methods (Vet et 
al., 2013). Only 58% of children were adequately sedated over the course of the study 
period. Over-sedation is particularly problematic, as it is associated with numerous 
clinical problems, including longer duration of mechanical ventilation, extubation failure, 
and greater cumulative drug exposure (Randolph et al., 2002), which contribute to 
development of medication tolerance, physical dependence and subsequent iatrogenic 
withdrawal syndrome (Fonsmark, Rasmussen, & Carl, 1999; Ista et al., 2008). Under-
sedation is equally detrimental, as the associated agitation and distress in a confused and 
disoriented child can result in accidental displacement of intravenous lines or 
endotracheal tubes (Sorce, 2005) and intolerance of mechanical ventilation (Cheifetz,  
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2003). Resulting complications can include unplanned endotracheal intubation, airway 
trauma, hemodynamic instability, and increased lengths of mechanical ventilation and 
higher mortality (Cheifetz, 2003; Playfor et al., 2006; Vet et al., 2013), not to mention 
distress for both patients and their parents (Playfor, Thomas, & Choonara, 2000). 
Tolerance  
Pharmacodynamic tolerance is a purely biochemical phenomenon, characterized 
by decreased efficacy of a drug over repeat exposures due to cellular adaptation to on-
going receptor binding, such that an increased dose or concentration of a drug is required 
to produce the same patient response (Barr et al., 2011; Jenkins, 2011). In animal and 
human models, opioid tolerance is mediated by opioid and N-methyl-D-aspartate 
(NMDA) receptors in the central nervous system. Normally, opioid-receptor binding 
causes activation of inhibitory G-proteins and down-regulation of intracellular adenylyl 
cyclase levels, which are responsible for the clinical effects of analgesia and sedation 
(Jenkins, 2011; Smith, 2009; Suresh & Anand, 2001). However, following opioid 
exposure, receptor desensitization leads to a paradoxical hyper-sensitization of this 
signaling pathway, mediated by down-regulation or internalization of opioid receptors 
and uncoupling of opioid receptors from inhibitory G-proteins (Suresh & Anand, 2001). 
Excitatory NMDA receptor interactions contribute to the development of opioid tolerance 
by increasing intracellular calcium and activating other neural depolarization pathways. 
The end result of these cell-level changes is hyperalgesia, or increased perception of pain 
and agitation, rather than the expected opioid-induced analgesia and sedation (Anand et 
al., 2010; Jenkins, 2011; Suresh & Anand, 2001).  
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Benzodiazepine tolerance is hypothesized to develop in a similar manner: drug 
binding to neuronal γ-aminobutyric acid (GABA) receptors leads to inhibitory effects on 
neurotransmission, but chronic exposure may cause receptor modifications and 
uncoupling, excitatory glutaminergic neurotransmission, and an increase in NMDA 
receptors (Allison & Pratt, 2003; Vinkers & Olivier, 2012). The current model suggests 
that a synergistic combination of most or all of these cellular changes causes 
benzodiazepine tolerance. 
Although the biochemical mechanisms underlying the development of tolerance 
are common across individuals, there is also variability in the degree of tolerance that 
patients develop, which may be impacted by factors unique to the individual. For 
example, in children in particular, age and developmental stage influence the 
pharmacodynamics of sedation therapy. The CYP2D6 and CYP34A enzymes involved in 
metabolism of opioids and benzodiazepines may not fully mature until 6 months of age, 
placing younger children at increased risk for altered responses to these medications 
(Johnson, Miller, & Hagemann, 2012; Mulla, 2010). Pharmacodynamic idiosyncrasies in 
the developmentally diverse PICU population present problems for clinicians to use these 
sedatives effectively and safely.  
Other studies have demonstrated racial and ethnic differences in drug metabolism 
as a consequence of pharmacogenetic variations within populations. Approximately 7% 
of the white population and up to 30% of the African American population possess 
alterations in the CYP2D6 enzyme associated with rapid metabolism, placing African 
Americans at greater risk of experiencing increased drug effects with typical doses  
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(Smith, 2009). Similarly, up to 34% of African American patients are affected by 
deficient CYP2D6 enzymes, increasing their risk for adverse drug reactions (Brennan, 
2012). Since tests of enzyme functionality are not routinely performed in the clinical 
setting, age, race and ethnicity may be the only surrogate variables available for 
understanding their potential mediating or moderating effects on the development of 
tolerance and physical dependence.  
Severity of illness and clinical status are complex variables impacting the 
metabolism of sedative drugs (Carcillo et al., 2003; Ince et al., 2012), and therefore the 
quality of sedation management and the duration of exposure to sedatives. Specifically, 
hepatic and/or renal impairment associated with critical illness may significantly increase 
the bioavailability of certain drugs, such as morphine (Brennan, 2012; Smith, 2009). 
Children in the PICU also may experience frequent and rapid changes in clinical status, 
and the extent to which multiple organ failure or other severe illness states influence 
sedation therapy and drug tolerance remains to be evaluated thoroughly, though limited 
research exists (Bergman, Steeves, Burckart, & Thompson, 1991; Dagan, Klein, Bohn, & 
Koren, 1994; Fonsmark et al., 1999; Hughes et al., 1994; Ince et al., 2012). Similarly, 
neurologic impairments and/or developmental delays may influence the way in which 
critically ill children respond to sedative agents, or exhibit behaviors typically managed 
with sedating medications. Similar to the unique nuances that the organizational context 
brings to bear on sedation management in the PICU, variability in patient response to 
analgesic and sedative medications presents a unique challenge in the study of drug 
tolerance, physical dependence and subsequent iatrogenic withdrawal syndrome. 
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Weaning and Iatrogenic Withdrawal Syndrome 
 After recovery from their primary illnesses, children are able to resume 
responsibility for ventilation and oxygenation, which begins the process of gradual 
weaning of mechanical ventilation and associated sedation. Discontinuation of 
mechanical ventilation without adequate sedation weaning can lead to respiratory 
depression necessitating endotracheal reintubation, which is associated with worse patient 
outcomes (Cheifetz, 2003). Failure to wean sedative therapy is also problematic, as it is 
directly related to IWS in physically dependent patients (Cho, O’Connell, Cooney, & 
Inchiosa, 2007; Darnell, Steiner, Szmuk, & Sheeran, 2010; Ducharme, Carnevale, 
Clermont, & Shea, 2005; Ista, van Dijk, Gamel, Tibboel, & de Hoog, 2007; Jacobs, 
Salman, Cotton, Lyons, & Brilli, 2001).  IWS is a cluster of physiologic signs and 
symptoms reflecting autonomic nervous, gastrointestinal and cardiovascular disruptions 
(e.g., elevated temperature, vomiting, tachycardia). Not only does IWS add to patient 
discomfort, but also it extends intensive care and hospital lengths-of-stay (Franck, 
Vilardi, Durand, & Powers, 1998), and creates stress for parents and caregivers (Johnson 
et al., 2012). The added costs can be considerable. 
Assessment and Management of IWS 
As pediatric critical care clinicians have come to acknowledge IWS as a 
complication of PICU care, a large volume of research has been directed towards 
identifying and assessing its severity. Two instruments were developed concurrently in 
the United States and the Netherlands, respectively, and tested for use in the PICU: the 
Withdrawal Assessment Tool-Version 1 (WAT-1) (Franck et al., 2008; Franck et al., 
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2012) and the Sophia Observation withdrawal Symptoms-scale (SOS) (Ista et al., 2008; 
Ista, de Hoog, Tibboel, Duivenvoorden, & van Dijk, 2013). The WAT-1 is an 11-item 
instrument that consists of four separate assessments performed by the bedside nurse: 
review of the patient’s medical record for the past 12 hours, direct observation of the 
patient at rest for 2 minutes, application of progressive stimulus with simultaneous 
patient assessment, and assessment of post-stimulus recovery time (Appendix 1).  The 
instrument was developed and validated for use in a sample of 83 pediatric patients 
between 2 weeks to 18 years of age who were recovering from acute respiratory failure 
and had received greater than 5 days of continuous or around the clock opioid 
medications (Franck et al., 2008). The WAT-1 screens for symptoms of IWS attributable 
to either opioid- or benzodiazepine-associated withdrawal, with scores ranging from 0 to 
12 points. A cutoff score of ≥ 3 is considered to be indicative of IWS and has high 
sensitivity and specificity (87% and 88%, respectively; area under the curve 0.94 ± 0.01 
[95% confidence interval (CI) 0.93-0.96]) (Franck et al., 2008). In addition to being used 
as a screening tool for the presence of IWS, peak WAT-1 scores have demonstrated high 
convergent validity with nurse ratings of withdrawal intensity (rs = 0.80), and were 
moderately correlated with lengths of opioid and benzodiazepine therapy in the pre-
weaning period and length of opioid weaning (Franck et al., 2008), providing further 
evidence for the instrument’s construct validity. Therefore, peak WAT-1 scores might 
also be used as an indicator of the severity of IWS symptoms. 
The Sophia Observation withdrawal Symptoms-scale (SOS) is another tool 
developed by pediatric experts for evaluating symptoms of IWS in critically ill children.  
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The SOS demonstrated very good reliability and validity in psychometric testing (83% 
and 93%, respectively), and a cutoff score of ≥ 4 yielded good sensitivity and specificity 
for identifying IWS (Ista et al., 2013; Ista, van Dijk, de Hoog, Tibboel, & 
Duivenvoorden, 2009). The authors suggest that the tool improves upon the WAT-1 by 
including more signs and symptoms of IWS, such as anxiety, grimacing, and tachycardia 
(Ista et al., 2008; Ista et al., 2009). However, a direct comparison of the two instruments 
has never been performed. Neither the WAT-1 nor the SOS is able to distinguish between 
opioid-related versus benzodiazepine-related IWS, since most pediatric patients receive 
both for sedation and are typically weaned from both concurrently (Ista et al., 2007). It is 
important to note that monitoring for IWS is not a standard practice in all institutions. 
The treatment of IWS is also an area of significant research interest. Currently, 
there are no evidence-based guidelines for the treatment of IWS in children; clinicians 
instead must rely upon their clinical judgment and guidelines for the management of 
neonatal abstinence syndrome in infants born to substance dependent mothers (American 
Academy of Pediatrics, 1998; Hudak, Tan, The Committee on Drugs, & The Committee 
on Fetus and Newborn, 2012). The American Academy of Pediatrics recently released a 
clinical report recommending that patients be transitioned to longer-acting opioid 
formulations, followed by 10-20% dose reductions of short-acting opioids every 24 to 48 
hours as tolerated until all opioids are discontinued in order to prevent IWS (Galinkin, 
Koh, The Committee on Drugs, & Section on Anesthesiology and Pain Medicine 2014). 
Benzodiazepine-related IWS has been treated with long-acting benzodiazepine 
supplementation, as well as substitution of phenobarbital (J. D. Tobias, 2000). Numerous  
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studies have evaluated the potential for other sedative medications to prevent (i.e., 
methadone) or manage the symptoms of IWS: clonidine, dexmedetomidine, and ketamine 
have all been found to effectively facilitate weaning from opioids and benzodiazepines 
(Anand et al., 2010; Aydogan et al., 2013; Hünseler et al., 2014; Lugo, MacLaren, Cash, 
Pribble, & Vernon, 2001; Meyer & Berens, 2001; Tobias, 2006; White & Karsli, 2007).  
It is important to note that IWS continues to develop in PICU patients despite the 
implementation of protocols intended to prevent it (Bowens et al., 2011; Ducharme, 
Carnevale, Clermont, & Shea, 2005; Johnson, Harrison, & Allen, 2010; Meyer & Berens, 
2001; Siddappa et al., 2003; Tobias, 2006). For example, few PICUs have integrated 
weaning protocols into their standards of care (Alexander, Carnevale, & Razack, 2002; 
Deeter et al., 2011; Ista, de Hoog, Tibboel, & van Dijk, 2009; Jin et al., 2007), and among 
those that have, protocol compliance remains a challenge (Burns, 2012; Guttormson et 
al., 2010). Although in a survey of US PICUs, 100% of physicians reported gradually 
weaning patients from sedative and analgesic drugs, 94% also reported that children 
experienced IWS symptoms on their units (Twite et al., 2004). This continued incidence 
of IWS is presumably related to the wide variation in both sedation and weaning 
protocols, and practice. 
Two decades of research has aimed to better characterize IWS and to define its 
precipitating factors. The two classically identified clinical factors impacting IWS are 
cumulative dose and duration of sedation. After Finnegan et al. (1975) first identified the 
phenomenon of withdrawal in neonates born to substance dependent mothers, Arnold et 
al. (1990) extended the concepts of tolerance and physiologic dependence to a  
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retrospective study of neonates sedated for extracorporeal membrane oxygenation 
(ECMO). They found that cumulative doses of fentanyl exceeding 1.5mg/kg and duration 
of ECMO (and therefore sedation) >5 days were significantly associated with higher odds 
of IWS (OR = 7.0 and 13.9, respectively). Katz, Kelly and Hsi (1994) subsequently 
conducted a prospective study of the occurrence of IWS in slightly older critically ill 
children (aged 1 week to 22 months) receiving mechanical ventilation and continuous 
infusions of fentanyl. They identified that a threshold cumulative fentanyl dose of 
1.6mg/kg and an infusion duration exceeding 9 days were 100% predictive of IWS. 
Meanwhile, Fonsmark, Rasmussen and Carl (1999) found no associations between IWS 
and cumulative morphine dose, but total doses of midazolam >60 mg/kg were associated 
with the incidence of IWS. Until recently, no threshold duration of therapy for 
benzodiazepines was associated with IWS; however, a retrospective study found that a 
duration of benzodiazepine therapy exceeding 5 days was predictive (Fernández-Carrión 
et al., 2013). 
Several cutoff doses and durations of therapy have been proposed (Amigoni et al., 
2014; Arnold et al., 1990; Dominguez, Lomako, Katz, & Kelly, 2003; Fonsmark et al., 
1999; Franck et al., 1998; Katz et al., 1994), but the diversity of patient populations in the 
PICU and variance in sedation, weaning, and assessment for IWS has resulted in a lack of 
consensus regarding contributors to IWS. These results strongly suggest that other 
contextual variables influence a child’s risk for developing IWS. The current biomedical 
model fails to adequately explain the ongoing incidence of IWS in critically ill children 
and differential susceptibility between patients. Therefore, the purpose of this dissertation  
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study was to investigate the development of IWS in critically ill children requiring 
sedation therapy by exploring variables at the levels of the individual patient, the process 
and the health care system. 
Operational Definitions  
Conceptual definitions of tolerance and IWS have been presented in the previous 
sections. However, for the purposes of the proposed study, a set of operational definitions 
is needed for key variables of interest that will be referenced throughout the three studies. 
In particular, standardized instruments were used to assess variables, beginning with the 
primary outcome of IWS. 
As discussed, the WAT-1 (Appendix 1) is an 11-item instrument developed for 
the purpose of detecting signs and symptoms of clinically significant IWS in children 
(Franck et al., 2008; Franck et al., 2012). Prior to the start of the RESTORE trial, all 
clinicians across the 31 participating institutions were trained in the use of WAT-1 
scoring and completed a post-test to ensure their comprehension of the material (Curley 
et al., 2015). After baseline training, each RESTORE nurse co-investigator provided five 
sets of paired WAT-1 ratings. Scores were evaluated for inter-rater reliability and 
maintained at greater than 90% throughout the study. Therefore, for the purposes of this 
dissertation work, WAT-1 scores were used as a valid and reliable indicator of the 
presence and severity of IWS in study subjects, with the outcome of clinically significant 
IWS being operationally defined as two or more non-consecutive WAT-1 scores ≥3. In 
the RESTORE trial, clinically significant withdrawal was defined as the need for rescue 
therapy (i.e., an opioid or benzodiazepine bolus or increase in opioid or benzodiazepine 
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infusion) after the start of weaning in order to manage worsening symptoms, which were 
identified using the WAT-1 (Grant, Scoppettuolo, Wypij, & Curley, 2012). However, due 
to variations in clinical practice across institutions, not all patients in the RESTORE trial 
exhibiting signs and symptoms may have received rescue therapy, particularly among 
control PICUs. In contrast, all sites were required to assess patients using the WAT-1 for 
symptoms of IWS during sedation weaning, and the threshold score of ≥ 3 has been 
psychometrically tested (Franck et al., 2008; Franck et al., 2012). Out of concern for 
potential false positives, the more conservative criterion of two WAT-1 scores ≥3 was 
used, which has not been previously tested for validity and reliability. 
A variety of analgesic and sedative medications are available for use in the PICU 
(Vet et al., 2013; Zuppa et al., 2005), but this study will focus on the specific 
contributions of opioids and benzodiazepines to the outcome of IWS. Total sedative 
exposure was measured by aggregating daily dosing of sedative medications in the 
RESTORE trial. All opiates were converted to morphine sulfate equivalents, and all 
benzodiazepines were converted to midazolam equivalents, according to standard 
conversions: morphine equivalent conversion factors to equal 1mg morphine sulfate were 
15µg remifentanil; 15µg fentanyl; 0.15mg hydromorphone; and 0.3mg methadone, and 
midazolam equivalent conversion factors to equal 1mg midazolam were 0.2mg 
clonazepam; 0.3mg lorazepam; and 2mg diazepam (Curley et al., 2015).  
A limitation of previous investigations is that they did not adequately differentiate 
between pre- and post-start of weaning medication doses, making previously proposed 
dose and duration thresholds unusable for prognostic purposes. Therefore, all medication- 
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related variables in this dissertation study were limited to the preweaning period: 
Cumulative doses (in milligrams per kilogram [mg/kg]) were calculated by summing 
continuous, scheduled and intermittent doses of each agent during the pre-opioid weaning 
period and dividing by the dosing weight. The mean daily dose was calculated by 
dividing the cumulative dose by the number of days the specific drug was administered. 
The peak daily dose was equal to the highest daily dose of each drug administered. 
Duration of opioid and/or benzodiazepine therapy was recorded based on the total 
number of days the patient received each agent.  
Although it is commonly supposed that children with previous sedative exposures 
have greater medication needs and thus are more likely to demonstrate tolerance with 
subsequent exposures, studies have failed to support such an association. Children with a 
history of opioid exposure do not have higher opioid requirements during or following 
surgery (Fanning, Stucke, Christensen, Cassidy, & Berens, 2012), and in fact tolerance 
appeared to occur less frequently among subjects with previous PICU admissions in one 
study (Anand et al., 2013). Therefore, a history of exposure to opioids and/or 
benzodiazepines was not examined in either the RESTORE trial or this secondary 
analysis, and was not expected to significantly impact the results. 
Tolerance was recently investigated in a multicenter observational study, in which 
it was defined as a doubling of the initial (i.e. first 24 hours’) opioid dose over the course 
of a patient’s hospitalization (Anand et al., 2013). In the absence of clear biomarkers for 
the development of tolerance, a clinically based definition is the closest available 
surrogate. For the purposes of this study, the current operational definition of tolerance 
was adapted to define tolerance as a doubling of the Day 2 opioid dose, with the caveat 
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that tolerance had to occur before the onset of opioid weaning. This modification was 
needed to adjust for potential sub-optimal dosing of the initial sedative regimen. 
Chapter Aims and Rationales 
Chapter 2: Specific Aims.  
The purpose of this systematic review of available literature was to identify 
known or potential risk factors contributing to the prevalence of iatrogenic withdrawal 
syndrome (IWS) in critically ill children. This paper presents a conceptual model of risk 
for IWS, which demonstrates the relationships among tolerance, the identified risk 
factors, and the outcome of clinically significant IWS. Furthermore, the results of this 
review provide the foundation for the data-based papers to follow. The manuscript was 
published in the January 2015 issue of Pediatric Critical Care Medicine.† 
Rationale. 
The conceptual model in this paper was developed through an inductive process 
of examining the literature and collapsing related risk factors into categories, without any 
basis in previous theories. However, the classic structure-process-outcome model 
implemented in healthcare research (Donabedian, 1966) provides a useful framework for 
understanding the conceptual distinctions made between variables at the process and 
system levels in this model of IWS risk. To summarize, the structure of a healthcare 
organization consists of characteristics that indirectly influence patient outcomes by 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
†The manuscript in Chapter 2 is the author’s original work and the copyright is as follows: 
Pediatric Critical Care Medicine: 1 January 2015 – Volume 16 – Issue 2 – p 175–183, Wolters 
Kluwer Health Lippincott Williams & Wilkins©. While the manuscript is reproduced free of 
charge, no modifications are permitted without the permission of the copyright holder. 
	  
21 
shaping the environment of care delivery. Typically these features remain stable over 
time, and include factors such as hospital size and staff professionalization (Hearld, 
Alexander, Fraser, & Jiang, 2008). In contrast, processes are care activities performed by 
individuals within the organization, which are by their nature dynamic and changing over 
time. The benefit of simultaneously considering patient-, process- and system-level 
factors together is the ability to identify potential interactions between process and 
systems variables that contribute to patient outcomes (Hearld et al., 2008), while 
adjusting for differences in patient populations across healthcare institutions. 
Chapter 3: Specific Aims. 
The purpose of this paper was to use data from baseline pre-randomization 
subjects in the RESTORE trial to further evaluate the relationships among tolerance, 
weaning, and IWS. Specifically, patterns of opioid and benzodiazepine weaning as they 
occurred in PICUs across the United States in typical practice settings was assessed and 
characterized. The information obtained about the effects of sedative dose, duration, and 
other clinical factors on tolerance and subsequent patterns of weaning provide key 
information for the construction of a predictive model in the final paper. This manuscript 
has been submitted for review for publication. 
Rationale. 
The pre-randomization RESTORE subjects provided a unique cohort for exploring 
the relationships of interest in this study, since similar data were collected as in the larger 
trial and subjects were assessed for pain, agitation, sedation and IWS using validated 
assessment instruments. Therefore, unlike other observational studies that may rely on 
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clinicians’ subjective assessments of these patient states or retrospective chart reviews, 
this dataset contained rigorously measured data points that reflected usual practice at each 
institution. Some of the participating PICUs had standardized sedation assessment 
processes already in place, but they were not necessarily being used to titrate or wean 
sedative therapy. These circumstances offered a view of usual practice prior to 
implementation of a standardized, goal-directed protocol. This dataset also provided a 
test group for developing a standard approach to defining start of opioid weaning, 
tolerance, and weaning patterns in a smaller, more manageable patient cohort.  
Chapter 4: Specific Aims. 
The purpose of this paper was to build upon the findings of the previous two 
investigations, in order to construct a predictive model of IWS risk using data from 
subjects in the RESTORE trial. The resulting model could be used as the foundation for a 
risk assessment tool that would help guide weaning and other preventive strategies in the 
clinical setting. This manuscript has been submitted for review for publication. 
Rationale. 
Up to this point, there have been a few attempts to identify risk factors for IWS 
(Amigoni et al., 2014; Dominguez et al., 2006; Dominguez et al., 2003; Fernández-
Carrión et al., 2013; Ista et al., 2013), which have met with varying degrees of success. 
Key limitations of these previous approaches have been: sampling from a single center, 
use of small study samples, and failure to distinguish between preweaning medication 
doses. Results of these analyses have been inconsistent, even with respect to the most 
widely reported risk factors of sedative dose and duration (Amigoni et al., 2014; 
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Dominguez et al., 2003; Fernández-Carrión et al., 2013). In addition, older studies have 
been hampered by a lack of standardized assessment instruments for IWS ((Birchley, 
2009).  
The convergence of a number of factors therefore supports the development of a 
new predictive model of IWS in this study. First, the recently completed RESTORE trial 
was the largest study of sedation management ever conducted in pediatric critical care, 
and the dataset was designed with the objective of evaluating IWS as a secondary 
outcome. Routine screening for IWS was performed using the WAT-1, a well-validated 
instrument that is being used in an increasing number of studies of IWS (Amigoni et al., 
2014; Fisher, Grap, Younger, Ameringer, & Elswick, 2013; Jeffries, McGloin, Pitfield, & 
Carr, 2012). Finally, the trial was multi-center, which provided the opportunity to 
examine the influence of a diverse group of providers and health systems on the outcome 
of interest, an area that has previously been underexplored in the literature. 
Strengths and Limitations 
 This dissertation had the benefit of using data from the largest clinical trial of 
sedation management ever conducted in pediatric critical care for secondary analysis. The 
research question of the RESTORE trial – whether pediatric patients with acute 
respiratory failure managed per a nurse-led, goal-directed sedation management protocol 
experienced fewer days of mechanical ventilation – was directly related to the outcomes 
of interest in the analyses to follow. Not only were relevant data points collected using 
the stringent site auditing, data monitoring and quality control processes of a large 
clinical trial, but the incidence of IWS was also a secondary outcome measure of the 
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RESTORE trial. Thus, it was both feasible and justifiable to conduct a secondary analysis 
of this existing data set to address the specific aims of this dissertation. 
 However, because two of the three studies were secondary analyses, the findings 
are limited by any weaknesses of the parent study. Although highly unlikely, site 
randomization of the RESTORE trial may have failed to yield a representative sample of 
critically ill children in the PICU, impacting generalizability of the results. Undetectable 
differences between the control and intervention sites may have occurred, potentially 
confounding the effect of the nurse-led, goal-directed intervention. Finally, this 
dissertation included process- and system-level variables in its analyses, based on an 
untested conceptual framework. Since clinical sites reported their data in aggregate, the 
influence of systems factors could not be linked to individual patients. Therefore, any 
conclusions drawn by this study regarding the contributions of system-level variables to 
the development of IWS will require prospective validation in future studies. Since 
prospective data collection did not take place for these dissertation analyses, both the 
approach and findings are limited to the data collected during the course of the RESTORE 
trial. 
Significance 
 The variables driving the development of IWS, beyond the biologic and 
pharmacologic level, are presently uncharacterized and pose a critical barrier to progress 
in IWS science. This study provides valuable evidence and context for understanding the 
phenomenon of IWS within the unique clinical circumstances in which it occurs. The 
results of these three studies will advance our current approach to management of 
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symptoms of IWS in the PICU. In particular, prospective validation of the predictive 
model of IWS risk contributed by this study is a logical next step towards a robust 
program of research, and further studies would harness these empirically demonstrated 
risk factors to support future projects, for example identifying biomarker changes 
associated with IWS in critically ill children.  
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Abstract 
Objective: Analgesia and sedation are common therapies in pediatric critical care, and 
rapid titration of these medications is associated with iatrogenic withdrawal syndrome 
(IWS). We performed a systematic review of the literature to identify all common and 
salient risk factors associated with IWS and build a conceptual model of IWS risk in 
critically ill pediatric patients.  
Data sources: Multiple databases, including PubMed/Medline, EMBASE, CINAHL, and 
the Cochrane Central Registry of Clinical Trials were searched using relevant terms from 
January 1, 1980 to August 1, 2014. 
Study selection: Articles were included if they were published in English and discussed 
IWS following either opioid or benzodiazepine therapy in children in acute or intensive 
care settings. Articles were excluded if subjects were neonates born to opioid- or 
benzodiazepine-dependent mothers, children diagnosed as substance abusers, or subjects 
with cancer-related pain; if data about opioid or benzodiazepine treatment were not 
specified; or if primary data were not reported. 
Data extraction and synthesis: In total 1395 papers were evaluated, 34 of which met the 
inclusion criteria. Most papers were prospective observational or interventional studies. 
To facilitate analysis, all opioid and/or benzodiazepine doses were converted to morphine 
or midazolam equivalents, respectively. A table of evidence was developed for 
qualitative analysis of common themes, providing a framework for the construction of a 
conceptual model.  
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Findings: The strongest risk factors associated with IWS include duration of therapy and 
cumulative dose. Additionally, evidence exists linking patient, process and system factors 
in the development of IWS.   
Conclusions: Given the state of existing evidence, well-designed prospective studies are 
required to better characterize IWS in critically ill pediatric patients. This review 
provides data to support the construction of a conceptual model of IWS risk that, if 
supported, could be useful in guiding future research. 
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Introduction 
Sedation is commonly used in pediatric intensive care to reduce the physiologic 
and psychological stress associated with critical illness. However, it is known that rapid 
weaning or abrupt cessation of sedation therapy in drug tolerant children precipitates 
iatrogenic withdrawal syndrome (IWS)1 – a cluster of symptoms that can have deleterious 
effects on patient recovery and hospitalization.2–4 
The prevailing mechanistic theory of drug tolerance involves receptor 
desensitization and up-regulation of excitatory intracellular pathways.5–7 Anand et al. 
provide a comprehensive review of physiologic mechanisms in pharmacodynamic 
tolerance.2 Clinically, tolerance manifests as a need for increased medication to achieve 
consistent therapeutic effects. Tolerance, escalating doses, and prolonged treatment are 
coupled with the development of physiologic dependence. Once patients manifest 
tolerance and dependence, termination of therapy without measured weaning precipitates 
IWS.3  
Most studies on opioid and benzodiazepine IWS have focused on characterizing 
symptoms in the pediatric population, developing screening and assessment tools, or 
testing treatment regimens. A fundamental question in understanding IWS has been 
overlooked: what specific factors predispose pediatric intensive care unit (PICU) patients 
to developing IWS? Knowledge of IWS risk factors and their inter-relationships may help 
clinicians prevent IWS. We performed a systematic review of the literature to identify all 
common and salient risk factors associated with IWS, with the intention of building a 
conceptual model of IWS that will guide future research.  
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Methods 
PubMed/Medline, EMBASE, CINAHL, and the Cochrane Central Registry of 
Clinical Trials were searched for original research on opioid- and/or benzodiazepine-
related IWS in critically ill children. Given the limited number of studies in this area, 
time limits were set between January 1, 1980 and August 1, 2014. Corresponding 
exploded MeSH or EMTREE terms were used when possible (Table 2-1).  
Articles published in English and discussing IWS following either opioid or 
benzodiazepine therapy in children in intensive care settings were included. Age limits 
were set from 2 weeks post-gestation to 18 years. Articles were excluded if data about 
opioid or benzodiazepine treatment were not specified; if primary data were not reported; 
or if subjects were neonates born to opioid- or benzodiazepine-dependent mothers, 
children diagnosed as substance abusers, or subjects with cancer-related pain.  Relevant 
reviews were referenced to capture key studies missed by the search criteria, using 
ancestry searching.  
Study data were extracted into tables of evidence and qualitatively synthesized. 
Examined data points included study population, location, sample size, sedative 
medications and mode of administration, IWS assessment method, weaning method, and 
number and percentage of IWS subjects. For cross-study comparisons, opioid and 
benzodiazepine doses were converted to morphine and midazolam equivalents. 
Specifically, morphine equivalent conversion factors to equal 1mg morphine sulfate were 
as follows: 15µg remifentanil; 15µg fentanyl; 0.15mg hydromorphone; and 0.3mg 
methadone.8 Midazolam equivalent conversion factors to equal 1mg midazolam were: 
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0.2mg clonazepam; 0.3mg lorazepam; and 2mg diazepam. Qualitative analysis of the 
retrieved articles’ results was used to identify both common and novel factors and 
construct categories of risk. The authors then used an iterative consensus process to 
develop a conceptual model describing IWS risk that was organized to include patient, 
process, or system factors contributing to IWS in pediatric patients.  
PRISMA guidelines were followed in the conduct and reporting of this study, 
including consultation with a research librarian in designing the search strategy.9 Selected 
studies were evaluated for quality using a criteria-based assessment method for 
randomized controlled trials (adequacy of randomization and blinding, presence of 
allocation concealment, and intention-to-treat analysis)10 and the Newcastle-Ottawa 
Quality Assessment Scale for observational studies.11 Randomized controlled trials were 
rated high, medium and low quality, with a single category deduction for each missing 
criterion. The Newcastle-Ottawa Quality Assessment Scale assigns star ratings for 
important elements of observational study design, with a maximum possible score of nine 
stars. Studies were rated high (7-9 stars), medium (4-6 stars) or low quality (1-3 stars) 
based on the total number of stars received. 
Results 
As outlined in Figure 2-1, 34 data-based articles met inclusion criteria for this 
review. Twenty-three studies reported combination opioid and benzodiazepine therapy 
(Table 2-2), while 9 reported opioid-only therapy (Table 2-3), and two reported 
benzodiazepine-only therapy (Table 2-4) (Supplemental Digital Content). 
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The majority of articles (74%) included <50 subjects. The incidence of either opioid- or 
benzodiazepine-related IWS (Figure 2-2) was widely variable; for example, frequency of 
IWS symptoms attributable to cessation of either opioids or benzodiazepines in studies of 
concurrent therapy ranged from 5%12 to 87%.13  
Common themes suggested three categories of risk factors associated with IWS: 
patient-, process-, and system-level factors, which were synthesized into a conceptual 
model (Figure 2-3) that organizes the presentation of evidence in this review. The 
majority of studies investigated patient-level variables, including age, criticality, duration 
of therapy and cumulative dose. Process-level factors were directly related to the 
approach of providing sedation, and included the use of sedation and/or IWS assessment 
tools and protocols. System-level factors were infrequently cited, but reflected structural 
variables that influence clinician practice within the healthcare system, such as 
interprofessional collaboration and protocol compliance.  Each will be presented in the 
following sections. 
Patient-Level Factors 
Age. Moderate quality evidence supports a relationship between age and IWS.14–
20 Prospective studies have shown that cumulative opioid dose is related to age,16 and that 
younger patients experience higher incidences of IWS.18 Similarly, among retrospective 
studies assessing the abrupt cessation of continuous fentanyl15 or midazolam infusions,19 
younger age was associated with neurologic symptoms of IWS, such as 
irritability/agitation and seizures.   
Older age was also associated with IWS in children.17 For example, subjects with 
the highest daily doses (morphine >60 µg/kg/hr or midazolam >250 µg/kg/hr) tended to 
33 
be older (median 6 years vs. 1.4; p=0.0017) even when doses were adjusted for weight.20 
These subjects also had a greater incidence of IWS: 40% of older subjects versus 12% of 
other subjects (p≤0.001). 
Criticality. Limited data from moderate quality studies suggests that severity of 
illness, particularly involving brain injury or ischemia, contributes to a higher incidence 
of IWS.19–24 Low serum albumin concentration in infants receiving midazolam in one 
retrospective study was associated with IWS-related neurologic disturbances.19 Several 
studies noted that children with pre-existing seizure disorders or hypoxemic brain injuries 
are more likely to experience IWS.20–23 
Duration of therapy. Many studies of varying quality related duration of opioid 
and/or benzodiazepine therapy to the incidence of IWS.1,4,8,16,17,25–35 Subjects with longer 
PICU or hospital lengths of stay,8,29 more ventilator days,8,29 and longer ECMO 
therapy4,28 were more likely to experience IWS. In one paper, subjects in a randomized 
trial of methadone-facilitated weaning were more likely to experience treatment failure 
with longer PICU lengths of stay, particularly after receiving fentanyl for ≥9 days.29 In 
two small studies, subjects experiencing IWS received at least 10 days of opioid or 
benzodiazepine therapy.34,35 
The majority of studies in this category directly evaluated relationships between 
length of opioid and/or benzodiazepine therapy and IWS.1,8,16,17,25–27,30–33,36 Some used 
statistical methods to establish predictive opioid thresholds, with cut-off lengths of 
therapy ranging from ≥527 to 8 days (OR=18, p= 0.02).25 Exposures longer than 9 days 
were 100% predictive of IWS.27 The remaining studies evaluated correlations between 
length of opioid infusion and IWS outcome or score,1,16,26,32 which ranged from 
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moderately (r=0.20, p=0.02)1 to strongly positive (r=0.70, p<0.05).26 Among prospective 
studies investigating the duration of opioid therapy and IWS, all exceeded the 5-day 
threshold proposed in previous research (Figure 2-4).1,8,12,16,17,25–27,30 
No widely accepted threshold duration of therapy for benzodiazepines currently 
exists, although a recent retrospective study found that a duration of benzodiazepine 
therapy exceeding 5 days had 83% sensitivity and 92% specificity for predicting IWS.36 
Positive correlations between duration of benzodiazepine therapy and IWS have been 
identified in other studies of concurrent opioid and benzodiazepine 
administration.1,8,17,30,31 Similar to opioid duration, these correlations are moderate, 
ranging from r=0.23 (p<0.01)8 to r=0.52 (p<0.001).30 In several prospective studies, 
subjects with IWS received benzodiazepine therapy in excess of 10 days (Figure 
2-5).12,21,30,37 
Dose. Strong reproducible evidence exists for a relationship between opioid 
and/or benzodiazepine dose and IWS.1,4,8,12–14,16,17,20,21,23–30,32,35,36,38–40 Description of 
dosing varied, with the most common measure being cumulative dose (total amount of 
drug administered during treatment). 
Several studies focused on the association between prescribed opioid dose and 
IWS risk4,16,24–28,36,38 Whereas one study found that a cumulative morphine equivalent 
dose of >106.7mg/kg was associated with 7-fold higher odds of IWS,28 another identified 
that a threshold cumulative dose of ≥166.7mg/kg (morphine equivalents) was 100% 
predictive of IWS.27 Lower thresholds have also been proposed in unique patient 
populations, for example, >80mg/kg doses after ECMO support (OR=13.0, p=0.003).4 
This threshold had 85% sensitivity and 70% specificity for predicting IWS. A more 
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recent retrospective study found that 32 mg/kg morphine equivalent doses had 83% 
sensitivity and 85% specificity for predicting IWS in children who received mean 
cumulative doses of midazolam above published averages.36 
Only one study of benzodiazepine-associated IWS compared cumulative dose 
with the incidence of withdrawal,14 finding that an infusion rate greater than 0.3mg/kg/h 
(midazolam equivalents) resulted in symptoms consistent with IWS. Cumulative dosages 
in midazolam equivalents ranged from 0.9mg/kg to 25.3mg/kg,14 but statistical analyses 
were not performed. However, in a study of mixed opioid and benzodiazepine 
administration, a cumulative benzodiazepine dose threshold of >60mg/kg (midazolam 
equivalents) was significant (p<0.05).23 
Many studies evaluating IWS symptoms attributable to either opioids or 
benzodiazepines reported dosage associations:1,8,12,13,17,20,21,23,29–31,34,35,39 one found 
moderate correlations with opioid dose alone,31 and four with both opioid and 
benzodiazepine dose.1,13,30,36 The remaining studies reported differences between groups 
with and without IWS in cumulative opioid and/or benzodiazepine doses,8,12,17,23,29,39 or 
had too few subjects for statistical analysis.21,34,35 The prospective studies were 
graphically compared with the dose thresholds proposed for opioids (Figure 2-6) and 
benzodiazepines (Figure 2-7), respectively. This analysis showed that many studies 
reported mean or median doses well below the proposed thresholds among subjects with 
IWS.1,12–14,17,21,30 
Process-Level Factors 
Sedation protocol.  Although several authors have noted the importance of 
standardized sedation protocols in reducing the incidence of IWS,12,40 little high-quality 
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evidence exists to directly illustrate the proposed relationship. Three studies cited the lack 
of a sedation management protocol as a risk factor for the development of IWS,12,31,40 and 
two moderate-quality studies showed reductions in IWS rates in the intervention groups 
when sedation protocols were implemented.12 
Drug choice.  Some evidence supports an association between drug choice and 
IWS.4,13,15,17,20,33,34 Specifically, four studies observed an association between fentanyl 
and IWS symptoms in children.4,13,15,41  Rates of IWS are lower in subjects receiving 
morphine rather than fentanyl infusions  (9% v. 57%; p=0.01).4,13 In a retrospective chart 
review of subjects who developed a “movement disorder” following discontinuation of 
infusions, fentanyl was the only medication common to all subjects (p<0.001).15  
Methadone has been evaluated in several studies as a potential weaning agent to 
prevent IWS symptoms in drug-tolerant pediatric patients.21,22,26,29,33,34,38,41 However, one 
study33 determined that the greatest risk factor for IWS among subjects receiving 
prophylactic methadone was inadequate methadone dosing. Multi-drug sedation therapy 
has also been proposed as an additional risk factor for IWS.17,41  
Mode of administration. Low to moderate quality articles reported more frequent 
IWS among subjects receiving continuous infusions of opioids and/or 
benzodiazepines.4,15,19,34,35,39,41 Although authors noted that continuous infusions could 
theoretically contribute to faster development of drug tolerance,4,19,22 none of the studies 
in this review specifically compared the effects of intermittent versus continuous 
administration on the incidence of IWS.  
Weaning. Fewer than half of the cited studies (43%) utilized a standardized 
weaning protocol,4,12,13,22,25,27,29,30,32–34,37 and even with a standard protocol, withdrawal 
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rates ranged from 5%12,34 to 87%.13 In the remaining studies, opioids, benzodiazepines, or 
both were either abruptly discontinued19,23,24,35 or weaned on a variable basis.1,8,14–
17,20,26,28,31,39–41 Weaning patterns differed substantially: in one prospective study, opioid 
dose changes in the first 24 hours of weaning ranged from −24mg/kg to +14mg/kg 
(morphine equivalents).16 Two studies reported that use of a weaning protocol could 
reduce the incidence of IWS.16,38 Some studies abruptly discontinued sedative therapy 
due to the substitution of other agents, such as clonidine,16,20,41 dexmedetomidine,16,39 
methadone,17,21,29,33,34,38,41 or ketamine.41 Despite prophylactic therapy, IWS still occurred 
in 5%34 to 33%33 of subjects. 
Sedation/withdrawal assessment. Although many studies of IWS have focused on 
instrument development,1,8,13,17,30 few studies have evaluated the influence of routine 
sedation assessment on the incidence of IWS. Some authors have commented on the 
issues of over-sedation and development of tolerance,16,38,40,42 but no studies have 
specifically evaluated relationships among adequate sedation, standardized assessment, 
and IWS.   
System-Level Factors 
Weaning sedation requires a time-sensitive titration plan that may not be able to 
be accomplished in the PICU when intensive care beds are limited. In addition, local 
hospital-based policies may not allow for the use of some sedatives agents outside the 
PICU.  No paper cited in this review evaluated the impact of PICU census, bed 
availability, or local policies regarding the use of sedatives in non-ICU areas on the 
incidence of IWS. 
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Management of critically ill children also necessitates an interprofessional team 
approach. Disagreements within the care team regarding optimal sedation can lead to 
inconsistencies in sedation practices that may predispose children to IWS.40 Failure of 
interprofessional collaboration, along with variability in training and experience with 
sedation management may influence compliance. Poor sedation or weaning protocol 
compliance has been shown to increase the incidence of IWS.38  
Discussion 
To date, the strongest risk factors associated with IWS include duration of therapy 
and cumulative dose. Less evidence exists for relationships with age, criticality, 
sedation/weaning protocols, and sedation/IWS assessment. This review found few 
prospective studies offering data specific to opioid- and/or benzodiazepine-related IWS 
risk factors. It was often necessary to search for any mention of associated risk and 
extrapolate risk from reported relationships with other variables. The proposed 
conceptual model (Figure 2-3) illustrates how the convergence of patient- and process-
level factors within a system context may contribute to IWS. 
Studies linking the duration of opioid therapy and IWS proposed that a threshold 
of ≥5 days25,27 was predictive of IWS (Figure 2-4). Duration of therapy as a risk factor for 
benzodiazepine-related IWS has not been demonstrated, although a 10-day duration30 
seems contributory (Figure 2-5). Authors found relationships between cumulative dose of 
opioid and/or benzodiazepine and duration of infusion,13,32,34 and cumulative 
benzodiazepine doses as risk factors,23 albeit from studies with small sample sizes and 
inconsistent results. The observed relationship between dose and duration may be too 
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interdependent to determine individual contributions to IWS. For example, a recent study 
found that the primary outcome of doubling of daily medication dose (tolerance) was 
more likely to occur with infusions lasting >7 days.43 
Several studies4,15,25,26 in this review reported IWS accompanying opioid doses 
below proposed thresholds, which is potentially attributable to patient-level variability 
(e.g., pharmacogenetics, body composition, criticality). Similarly, cumulative dose as a 
risk factor for benzodiazepine-related IWS is not adequately supported in the current 
literature, as IWS was seen in subjects receiving less than the proposed threshold. Other 
factors such as criticality may obscure the relationships among dose, duration and IWS. 
Physiologically, as illustrated in the conceptual model, a patient’s therapeutic regimen – 
medication doses, duration of therapy, and mode of administration – may all act 
synergistically in contributing to the development of tolerance. 
Age, size, and dosing weight are interrelated, so the observation that older 
children tend to receive higher doses of opioids and benzodiazepines 20 is not surprising. 
Furthermore, drug metabolism and excretion, and behavioral responses to discomfort, are 
related to a child’s development.44 Studies in this review included different age ranges, 
further complicating this picture. More studies with adequate representation of all age 
groups are required to demonstrate a more definitive relationship with IWS risk. 
Inconsistencies in weaning protocols complicate the analysis of IWS risk, since 
abrupt cessation or rapid weaning has been shown to precipitate withdrawal 
symptoms.2,8,29,42,45 The lower incidence of IWS in studies with specified weaning 
protocols12,29,30,37 may be an indication of the importance of a weaning plan on IWS risk. 
Conversely, the fact that IWS occurred in controlled, prospective studies with 
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standardized weaning protocols21,33,34 suggests that protocol compliance or failure leading 
to IWS must be addressed. 
Among opioids, fentanyl has a greater potential for inducing tolerance due to its 
shorter half-life and greater opioid receptor affinity.2 More articles in this review reported 
IWS in subjects receiving fentanyl than with any other opioid.4,13,15,41 In addition, most of 
the studies that reported IWS in patients receiving continuous infusions also administered 
fentanyl,4,15,19,34,39,40 which could be the mechanism driving the proposed relationship 
between mode of administration and IWS. However, given the prevalence of fentanyl 
use, higher administered doses of both opioids and benzodiazepines before the start of 
weaning, and longer durations of therapy,1,8 other confounding factors may have 
influenced the outcome of IWS.13 This review presents evidence indicating that fentanyl 
is more likely to cause IWS than other opioids, but more research is necessary. 
Only half of the studies used validated instruments to assess subjects’ 
IWS.1,4,8,12,13,16,17,21,22,25–30,38,39 Finnegan’s Neonatal Abstinence Score (NAS) tool has not 
been validated outside of the neonatal population,46 despite its use in a quarter of the 
studies in this review. Establishing the validity and generalizability of other IWS 
assessment instruments is challenging, and studies applying validated IWS assessment 
tools (e.g. WAT-1,1,8 SOS17,47) are needed. IWS will remain difficult to quantify 
objectively until biological markers are available. 
Analysis of the literature reveals an evolving discussion of IWS risk in terms of 
tolerance- and non-tolerance-related factors. Drug choice, duration of therapy, mode of 
administration, and cumulative dose may be substitute measures for tolerance. Age and 
criticality are patient-level variables that may constitute risks for IWS independent of 
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tolerance. Process-level variables related to clinician decision making, which may be 
driven by policies of the larger healthcare system, also contribute to IWS risk but not 
tolerance. However, system-level factors have not been consistently recognized or 
explored in the existing literature. For example, there is consensus that weaning sedation 
requires a time-sensitive titration plan that may not be able to be accomplished in the 
PICU when intensive care beds are limited. Providers may need to move patients out of 
the PICU as soon as their primary condition has stabilized. In addition, local policies may 
not allow the use of some sedatives agents in non-ICU areas, further limiting providers’ 
ability to maintain a consistent weaning plan in some children. However, none of these 
factors were addressed in the articles assembled in this review. Further research is needed 
to examine the effect of system-level factors on patients’ risk for developing IWS.   
This study has important limitations. Small sample sizes were problematic for 
achieving requisite statistical power in several included studies, and the overall quality of 
the available data was moderate. In addition, due to the authors’ limitations, articles 
published in languages other than English could not be included in this review. This 
review was performed according to the PRISMA statement, where applicable, although 
an assessment of the risk of bias for each study was not performed. A registered protocol 
also was not used in the conduct of this review. A meta-analysis of the selected studies 
could not be completed, due to low levels of evidence and significant heterogeneity in the 
populations of the included studies. 
Conclusion 
This is the first systematic review of risk factors associated with IWS in the 
critically ill pediatric population that identifies risk factors at the level of the patient, 
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process, and system, and describes their relationship with the development of tolerance to 
opioids and benzodiazepines. Of all the factors identified, duration of therapy and 
cumulative dose are the most predictive of IWS, as has been suggested by other authors. 
However, this review particularly highlights the need to further explore process and 
system variables, such as sedation/IWS assessment, and protocol adherence. There are 
many remaining questions for future studies on risk factors associated with IWS. This 
model can be used to guide the design and reporting of future studies on IWS in critically 
ill children. 
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Figures and Tables 
Figure 2-1. Systematic search and selection process 
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Figure 2-2. Proportion of subjects with IWS relative to the total number of subjects 
among included studies  
	  
Note: Mixed includes studies where the subjects received both opioids and benzodiazepines. 
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Figure 2-3. Risk for Iatrogenic Withdrawal Syndrome (IWS).  Conceptual model relating 
three levels of risk factors for IWS in critically ill children 
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Figure 2-4. Cross-study comparison of duration of opioid therapy in opioid-only and 
mixed agent (i.e. opioid and benzodiazepine administration) studies, among subjects with 
IWS 
	  
Reference for 5 day threshold: Katz, Kelly, & Hsi (1994)27 
Note: Bars represent mean ± SD, median and IQR, or median and min-max, as data were reported 
in the original studies; the size of each square corresponds to the size of the study sample, with 
increasing size for larger samples. 
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Figure 2-5. Cross-study comparison of duration of benzodiazepine therapy among 
subjects with IWS 
	  
* Duration includes medication taper; ** Reported duration only applies to 9 patients receiving 
lorazepam; ***Authors did not specify medication for the listed duration of sedation.    
Reference for 10 day threshold: Ista, et al. (2008)30 
Note: Bars represent mean ± SD, median and IQR, or median and min-max, as data were reported 
in the original studies; the size of each square corresponds to the size of the study sample, with 
increasing size for larger samples.	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Figure 2-6. Cross-study comparison of cumulative dose of opioids among subjects with 
IWS 
	  
* Provided dose range for total study group, not IWS subjects specifically; ** Values not 
calculated in original study. 
Reference for 106.7 mg/kg (morphine equivalents) threshold: Arnold, Truog, & Orav (1994)28 
Note: Bars represent mean ± SD, median and IQR, or median and min-max, as data were reported 
in the original studies; the size of each square corresponds to the size of the study sample, with 
increasing size for larger samples. 
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Figure 2-7. Cross-study comparison of cumulative dose of benzodiazepines among 
subjects with IWS 
	  
* Values not calculated in original study; ** Provided dose range for total study group, not IWS 
subjects specifically 
Reference for 60 mg/kg (midazolam equivalents) threshold: Fonsmark, Rasmussen, & Carl 
(1999)23 
Note: Bars represent mean ± SD, median and IQR, or median and min-max, as data were reported 
in the original studies; the size of each square corresponds to the size of the study sample, with 
increasing size for larger samples. 
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Table 2-1. Detailed search strategy 
Medline/PubMed AND CINAHL search strategy for pediatric studies 
Search Terms 
#1 ventilator* OR ventilation* OR respirator* OR "Respiration, artificial"[Mesh] OR 
"artificial respiration" 
#2 weaning OR weaned OR weans OR wean OR discontinue OR terminat* 
#3 hypnotic* OR depressant* OR sedat* OR opioid* OR narcotic* OR benzodiazepine* 
OR fentanyl OR morphine* OR diazepam OR lorazepam OR midazolam 
#4 #1 AND #2 AND #3 
Filters: English; Child: birth (manual exclusion of < 2 weeks)-18 years 
 
EMBASE search strategy for pediatric studies 
Search Terms 
#1 “ventilator” OR “ventilation” OR “respirator” OR "artificial respiration" OR artificial 
ventilation/exp OR assisted ventilation/exp 
#2 “weaning” OR “weaned” OR “weans” OR “wean” OR “discontinue” OR “terminate” 
OR “termination” [NOTE: No EMTREE term for ventilator weaning] 
#3 “hypnotic” OR “depressant” OR “sedative” OR hypnotic sedative agent/exp OR 
“opioid” OR “narcotic” OR opiate/exp OR narcotic agent/exp OR “benzodiazepine” 
OR benzodiazepine/exp OR fentanyl OR morphine OR diazepam OR lorazepam OR 
midazolam 
#4 #1 AND #2 AND #3 
Limits: English; Child: birth (manual exclusion of < 2 weeks)-18 years 
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Table 2-2. Articles on concurrent opioid and benzodiazepine therapy 
Study Site Sample 
Size 
Medications Mode of 
Administration 
IWS 
Assessment  
Randomized Control Trial 
Bowens et al. 
(2011)29 
PICU 
(US) 
N = 78 Fentanyl, midazolam Continuous MNWS 
Prospective Interventional 
Jin et al.  
(2007)12 
PICU 
(Korea) 
N  = 53 Fentanyl, midazolam Bolus, continuous Modified 
NAS, 
physiologic 
s/sx 
Prospective Observational 
Ista et al. 
(2013)17 
PICU 
(Nether-
lands) 
N = 154 Fentanyl, midazolam, 
morphine 
Continuous SOS 
Franck et al. 
(2012)1  
PICU 
(US) 
N = 126 Not specified 
(converted to 
morphine & midaz 
equivalents) 
Bolus, continuous WAT-1 
Franck et al. 
(2008)8 
PICU 
(US) 
N = 83 Not specified 
(converted to 
morphine & midaz 
equivalents) 
Bolus, continuous WAT-1, NRS 
of RN 
clinical 
judgment 
Ista et al.  
(2008)30 
PICU 
(Nether-
lands) 
N = 79 Fentanyl, midazolam, 
morphine 
Continuous SBOWC 
Ducharme et al. 
(2005)31 
PICU 
(Canada) 
N = 27 Fentanyl, midazolam Continuous  Physiologic 
s/sx 
Franck et al. 
(2004)13 
CICU 
(UK) 
N = 15 Fentanyl, lorazepam, 
midazolam, morphine 
Continuous OBWS 
Meyer & Berens 
(2001)21 
PICU 
(US) 
N = 29 Fentanyl, lorazepam, 
methadone, morphine 
Continuous, PO NAS 
Retrospective Chart Review 
Fernández-
Carrión et al. 
(2013)36 
PICU 
(Spain) 
N = 48 Fentanyl, midazolam Continuous NAS 
Johnson et al. 
(2010)32 
Academi
c hospital 
(US) 
N = 15 Fentanyl, midazolam Continuous, 
transdermal 
Physiologic 
s/sx 
Bachiocco et al. 
(2006)22 
NICU 
(Italy) 
 N = 20 Fentanyl, morphine Continuous NAS, clinical 
judgment of 
NICU RNs 
and MDs 
Tobias  
(2006)39 
PICU 
(US) 
N = 7 Fentanyl, midazolam Bolus, continuous NAS 
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Cont’d from previous page 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weaning Method  IWS Incidence (N, %) Risk Factors Study Quality 
 
Standard protocol Low-dose: 9/41 (22%);  
High-dose: 4/37 (11%) 
Dose; duration Moderate 
 
Standard protocol Intervention: 1/21 (5%);  
Control: 7/20 (35%) 
Dose; sedation 
protocol 
Moderate 
 
Variable 74/154 (48%) Age; dose; duration; 
drug choice 
High 
Variable 21/126 (17%) Dose; duration Moderate 
Variable 53/83 (64%) Dose; duration Moderate 
Standard protocol 27/79 (34%) Dose; duration High 
Variable Not reported Duration; sedation 
protocol 
Moderate 
Standard protocol 13/15 (87%) Dose; drug choice Moderate 
Standard protocol 3/29 (10%) Criticality; dose  Moderate 
 
 
 
 
 
Variable 24/48 (50%) Dose; duration Moderate 
Standard protocol 7/15 (47%) Dose; duration Moderate 
Variable  3/20 (15%) Criticality Moderate 
Variable N/A Dose; mode of 
administration 
Low 
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Cont’d from page 63 
Study Site Sample 
Size 
Medications Mode of 
Administration 
IWS 
Assessment  
Siddappa et al. 
(2003)33 
PICU 
(US) 
N = 30 Fentanyl, lorazepam, 
midazolam, 
methadone, 
sufentanil, 
remifentanil 
Continuous Physiologic 
s/sx 
Jacobs et al. 
(2001)18 
PICU 
(US) 
N = 133 Fentanyl, lorazepam, 
midazolam, morphine 
Continuous Clinical 
judgment of 
PICU RNs 
and MDs 
Lugo et al. 
(2001)34 
PICU N = 22 Fentanyl, midazolam, 
methadone 
Continuous Physiologic 
s/sx 
Fonsmark et al. 
(1999)23 
Med-
surg ICU 
(Denmar
k) 
N = 40 Midazolam, 
morphine, 
pentobarbital 
Bolus, continuous Physiologic 
s/sx 
Carnevale & 
Ducharme  
(1997)40 
PICU 
(Canada) 
N = 5 Fentanyl, midazolam, 
morphine 
Bolus, continuous Physiologic 
s/sx 
Sheridan et al. 
(1994)35 
Burn unit 
(US) 
N = 24 Midazolam, 
morphine 
Continuous Clinical 
judgment of 
MDs 
Bergman et al.  
(1991)19 
ICU 
(US) 
N = 45 Fentanyl, midazolam Bolus, continuous Physiologic 
s/sx 
Surveys 
Jenkins et al. 
(2007)20 
PICU 
(Multi-
site, UK) 
N = 20 24 different agents 
reported 
Bolus, continuous Clinical 
judgment of 
PICU MDs 
Twite et al. 
(2004)41 
PICU 
(Multi-
site, US) 
N = 35 Fentanyl, lorazepam, 
midazolam, morphine 
Continuous Not reported 
 
Legend of abbreviations (listed alphabetically): CICU – Cardiac Intensive Care Unit; CT – 
cardiothoracic; D/C – discontinuation; ICU – Intensive Care Unit; MDs – attending physicians; 
MNWS – Modified Narcotic Withdrawal Scale (adapted from Finnegan NAS monitoring tool); 
NAS – Finnegan’s Neonatal Abstinence Score; NICU – Neonatal Intensive Care Unit; NR – not 
reported; NRS – Numeric Rating Scale; OBWS – Opioid Benzodiazepine Weaning Scale; PICU 
– Pediatric Intensive Care Unit; PO – oral administration; RCT – randomized controlled trial; RN 
– registered nurse; s/sx – signs and symptoms; SBOWC – Sophia Benzodiazepine-Opioid 
Withdrawal Checklist; SOS – Sophia Observation withdrawal Symptoms scale; UK – United 
Kingdom; US – United States; WAT-1 – Withdrawal Assessment Tool-Version 1 
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Cont’d from previous page 
	  
	   	  
Weaning 
Method  
IWS Incidence (N, 
%) 
Risk Factors Study Quality 
Standard 
protocol 
10/30 (33%) Duration; drug 
choice 
Moderate 
NR 34/133 (26%) Age Moderate 
Standard 
protocol 
1/22 (5%) Duration; drug 
choice; mode of 
administration 
Moderate 
Abrupt D/C 14/40 (35%) Criticality; dose Low 
Variable N/A Dose; sedation 
protocol; systems 
factors 
Low 
NR 2/24 (8%) Dose; duration; 
mode of 
administration 
Low 
Abrupt D/C 5/45 (11%) Age; criticality; 
mode of 
administration 
Moderate 
 
Variable 34/335 (10%) Age; criticality; 
dose; drug choice  
N/A 
Variable 65.7% of fellowship 
directors 
Drug choice; mode 
of administration 
N/A 
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Table 2-3. Articles on opioid therapy only 
Study Site Sample 
Size 
Medications Mode of 
Administration 
Withdrawal 
Assessment Method 
Prospective Interventional 
Dominguez et al. 
(2003)25 
NICU 
(US) 
N = 19 Fentanyl Continuous NAS 
Prospective Observational 
Fisher et al.  
(2013)16 
PICU 
(US) 
N = 26 Fentanyl, 
morphine 
Bolus, 
continuous 
WAT-1 
Franck et al.  
(1998)4 
NICU N = 34 Fentanyl, 
morphine 
Bolus, 
continuous 
Opioid weaning 
flowsheet (adapted 
from NAS) 
Dagan et al. 
(1994)24 
PICU 
(Canada) 
N  = 7 Morphine Continuous Physiologic s/sx 
French & Nocera  
(1994)26 
PICU 
(US) 
N = 12 Fentanyl Bolus, 
continuous 
NAS 
Katz et al.  
(1994)27 
PICU 
(US) 
N = 23 Fentanyl Continuous NAS 
Retrospective Chart Review 
Jeffries et al. 
(2012)38 
PICU 
(Canada) 
N = 43 Morphine, 
methadone 
Bolus, 
continuous 
WAT-1 
Lane et al.  
(1991)15 
PICU 
(US) 
N = 13 Fentanyl Continuous Physiologic s/sx, 
clinical judgment of 
PICU MDs 
Arnold et al. 
(1990)28 
NICU 
(US) 
N = 37 Fentanyl, 
sufentanil 
Continuous NAS 
 
Legend of abbreviations (listed alphabetically): MDs – attending physicians; NAS – Finnegan’s 
Neonatal Abstinence Score; NICU – Neonatal Intensive Care Unit; PICU – Pediatric Intensive 
Care Unit; RN – registered nurse; s/sx – signs and symptoms; UK – United Kingdom; US – 
United States; WAT-1 – Withdrawal Assessment Tool-Version 1 
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Cont’d from previous page 
Weaning Strategy Incidence of IWS Risk Factors Study Quality 
 
Standard protocol 10/19 (53%) Dose; duration Moderate 
 
Variable 11/25 (44%) Age; dose; duration; 
weaning protocol 
Moderate 
Standard protocol Fent: 13/23 (57%); 
Morphine: 1/11 (9%) 
Dose; drug choice; 
duration; mode of 
administration 
Moderate 
No weaning 2/7 (29%) Dose Low 
Variable 6/12 (50%) Dose; duration Low 
Standard protocol 13/23 (57%) Dose; duration Moderate 
 
Standard protocol 18/43 (42%) Dose; weaning 
protocol; withdrawal 
assessment; systems 
factors 
Moderate 
Variable 5/13 (39%) Age; drug choice; 
mode of 
administration 
Moderate 
Variable 21/37 (57%) Dose; duration Low 
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Table 2-4. Articles on benzodiazepine therapy only 
Study Site Sample 
Size 
Medications Mode of 
Administration 
Withdrawal 
Assessment Method 
Prospective Interventional 
Dominguez et al. 
(2006)37 
PICU 
(US) 
N = 29 Lorazepam Continuous Clinical judgment of 
PICU MDs 
Prospective Observational 
Hughes et al.  
(1994)14 
PICU 
(UK) 
N = 53 Midazolam Continuous Clinical judgment of 
bedside and research 
RNs; non-validated 
s/sx checklist 
 
Legend of abbreviations (listed alphabetically): MDs – attending physicians; PICU – Pediatric 
Intensive Care Unit; RN – registered nurse; s/sx – signs and symptoms; UK – United Kingdom; 
US – United States 
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Cont’d from previous page 
Weaning Strategy Incidence of IWS Risk Factors Study Quality 
 
Standard protocol 7/29 (24%) None Moderate 
 
Variable 9/53 (17%) Age; dose Low 
	  
	  
	  
	  
	  
	  
	  
  
65 
 
	  
CHAPTER 3 
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Abstract 
Objective: To characterize sedation weaning patterns in typical practice settings among 
children recovering from critical illness. 
Design: A descriptive secondary analysis of data that were prospectively collected during 
the pre-randomization phase (January to July 2009) of a clinical trial of sedation 
management.  
Setting: Twenty-two pediatric intensive care units across the United States. 
Patients: The sample included 145 patients, aged 2 weeks to 17 years, mechanically 
ventilated for acute respiratory failure who received ≥5 consecutive days of opioid 
exposure. 
Measurements and Main Results: Group comparisons were made between patients with 
an inconsistent weaning pattern, defined as a ≥20% increase in daily opioid dose after the 
start of weaning, and the remaining patients defined as having a consistent weaning 
pattern. Demographic and clinical characteristics, opioid tolerance, and iatrogenic 
withdrawal symptoms were evaluated. Sixty-six patients (46%) were inconsistently 
weaned; 79 patients were consistently weaned. Prior to weaning, inconsistently weaned 
patients received higher peak and cumulative doses and longer exposures to opioids and 
benzodiazepines, demonstrated more opioid tolerance (39% vs. 24%), and received more 
chloral hydrate and barbiturates compared to consistently weaned patients. During 
weaning, inconsistently weaned patients assessed for withdrawal had a higher incidence 
of Withdrawal Assessment Tool-Version 1 scores ≥3 (85% vs. 46%), and received more 
sedative classes compared to consistently weaned patients. 
67 
Conclusions: This study characterizes sedative administration practices for pediatric 
patients prior to and during weaning from sedation after critical illness. It provides a 
novel methodology for describing weaning in an at-risk pediatric population that may be 
helpful in future research on weaning strategies to prevent iatrogenic withdrawal 
syndrome.  
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Introduction 
 Most children supported on mechanical ventilation in the pediatric intensive care 
unit (PICU) receive opioids and benzodiazepines for sedation during the critical phase of 
their illness.  Sedation is necessary to help the child mitigate the noxious effects of 
invasive therapies [1,2]. An estimated 16% to 35% of mechanically ventilated children 
become tolerant to sedative medications while in the PICU [3], defined as diminishing 
clinical effectiveness of a drug over the course of treatment [4,5]. However, as children 
recover from critical illness sedative medications are discontinued or weaned over time. 
The amount of time spent weaning is a balance between keeping a child comfortable and 
free from significant withdrawal symptoms that can complicate recovery and minimizing 
PICU and hospital lengths of stay [5,6]. Abrupt discontinuation or too rapid weaning of 
opioids and/or benzodiazepines in physically dependent children results in iatrogenic 
withdrawal syndrome (IWS), a cluster of physiologic signs and symptoms that includes 
nervous system hyperirritability, autonomic system dysregulation, gastrointestinal 
dysfunction, and motor abnormalities [4,5,7,8].  
The evidence informing optimal weaning practices is not robust [1,9]. It is known 
that children experiencing longer durations of sedative therapy (>5 to >9 days opioids 
[10,11]; >5 days benzodiazepines [12]) and higher cumulative doses (>1.2 mg/kg to >2.5 
mg/kg fentanyl [6,10,11,13]; >60 mg/kg midazolam [14]) are more likely to become 
tolerant [3,13] and experience IWS [6,10,11,13], which may necessitate a longer duration 
of weaning [4,8]. However, data on patient risk for protracted weaning and IWS are more 
than a decade old, and the distinction between preweaning and cumulative sedative 
exposure is often unclear. Nevertheless, current recommendations for sedation weaning 
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include decreasing total doses by 10% to 20% every 24 to 48 hours as tolerated by the 
patient and/or sedation substitution with long-acting formulations [4,15]. Published 
reports of sedative tapering often exceed these rates [16] with an unclear sequence of 
opioid and/or benzodiazepine dose tapering [12,15]. Protocols using methadone weaning 
regimens can be problematic because of variable implementation and patient response 
[17,18]. Other sedative medications, such as dexmedetomidine, clonidine, and ketamine, 
have been introduced but their contribution to successful weaning is unknown. 
Given that there are now more sedative agents and nuanced approaches to 
sedation therapy, it is worth re-examining our understanding of which patients can or 
cannot tolerate rapid weaning, especially since the optimal approach to sedative titration 
remains elusive. Moreover, the pattern and time course of opioid and benzodiazepine 
weaning in children recovering from critical illness remains poorly characterized. 
Clinician approaches to weaning may vary substantially [16] even in the presence of 
standardized sedation protocols. Greater understanding of the different patterns of 
weaning and their association with specific patient characteristics, such as clinical signs 
of IWS, may expedite the weaning process in at-risk patients. The purpose of this study 
was to characterize patterns of weaning in the context of current practice and to compare 
the characteristics of children with different patterns of weaning during recovery from 
critical illness. 
Materials and Methods 
Design: This study was a secondary analysis conducted on prospective data from 
the baseline, pre-randomization phase of the Randomized Evaluation of Sedation 
Titration fOr Respiratory FailurE (RESTORE) clinical trial. RESTORE was a multicenter 
70 
study designed to test a sedation management protocol in critically-ill pediatric patients 
with acute respiratory failure, defined as acute lung disease involving the airway and/or 
lung parenchyma [19]. During the baseline, pre-randomization phase (January to July 
2009), all enrolled patients received usual care in 22 participating centers, but each PICU 
implemented the same pediatric-specific assessment tools for pain, sedation and IWS 
[20,21]. Sedation management was otherwise unrestricted. Institutional Review Board 
approval was obtained from each participating site. Consent for data collection was 
obtained from the parents and/or legal guardians of each patient. 
Study population: Patients aged 2 weeks (≥42 weeks postmenstrual age) to 17 
years were included if they were intubated and mechanically ventilated for acute 
respiratory failure [19]. This analysis was restricted to baseline phase patients exposed to 
≥5 consecutive days of opioids from continuous infusions, scheduled intermittent, or as 
needed bolus doses; who completed opioid weaning within the 28-day data collection 
period without transfer or redirection of care; and who survived to hospital discharge. 
This restriction allowed for the full evaluation of a patient’s completed course of sedation 
therapy and the identification of individual patient patterns of weaning from sedation. 
Variables and measures: Demographic and clinical data collected at enrollment 
included patient age, gender, race, ethnicity, Pediatric Cerebral Performance Category 
(PCPC) and Pediatric Overall Performance Category (POPC) [22], baseline verbal 
ability, mortality risk (PRISM III-12) [23], reason for intubation, pediatric acute 
respiratory distress syndrome (PARDS) criteria [24], and past medical history. The PCPC 
and the POPC are measures developed to describe cognitive impairment and functional 
morbidity in children, respectively [25]. Each measure is a six-point scale of increasing 
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disability ranging from normal function to death [22,25]. The Pediatric Risk of Mortality 
(PRISM) III-12 score is a third-generation tool for estimating risk of PICU mortality 
based upon a patient’s age, operative status, and values for 17 physiologic variables 
measured within the first 12 hours after PICU admission [23]. Higher scores indicate 
greater physiologic instability and higher risk of mortality. PARDS classifications were 
defined according to published criteria from the Pediatric Acute Lung Injury Consensus 
Conference Group [24]. Hospital course variables included lengths of mechanical 
ventilation, PICU stay, and hospital stay. 
Medication data included receipt of neuromuscular blockade, cumulative and 
peak daily opioid dosage (in morphine equivalents per kg of body weight), cumulative 
and peak daily benzodiazepine dosage collected to the end of opioid weaning (in 
midazolam equivalents per kg of body weight), and administration of any other sedative 
medications (e.g., chloral hydrate, clonidine, dexmedetomidine, ketamine, pentobarbital, 
phenobarbital, and propofol). Daily and cumulative sedative medication doses were 
compared using standard equivalencies [19]. Specifically, morphine equivalent 
conversion factors to equal 1mg morphine sulfate were as follows: 15µg remifentanil; 
15µg fentanyl; 0.15mg hydromorphone; and 0.3mg methadone. Midazolam equivalent 
conversion factors to equal 1mg midazolam were: 0.2mg clonazepam; 0.3mg lorazepam; 
and 2mg diazepam. Sedative data were collected daily from endotracheal intubation, 
initiation of assisted breathing for patients with tracheostomies, or PICU admission for 
patients intubated at an outside hospital (Day 0) until 72 hours after their last opioid dose, 
hospital discharge, or Day 28 (whichever occurred first). Thresholds for opioid and 
benzodiazepine exposure from previous investigations of IWS were examined 
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[6,11,13,14]. Tolerance to the sedative effect of opioids was defined as a doubling of the 
Day 2 opioid dose prior to the start of weaning, an adaptation of Anand et al. [3] who 
defined tolerance as a doubling of the initially effective dose received during the first 24 
hours of therapy. Using Day 2 data provided a more conservative approach to quantifying 
tolerance in cases where subjects may have been started on sub-optimal initial doses and 
required titration to achieve clinical effect.  
Patients were assessed for signs of IWS using the Withdrawal Assessment Tool – 
Version 1 (WAT-1) [20,26]. The WAT-1 is an 11-item (12-point) instrument that 
includes a review of the patient’s medical record for the past 12 hours; direct observation 
of the patient for 2 minutes pre-stimulation; patient response to stimulation [27]; and 
assessment of post-stimulus recovery [26]. WAT-1 scoring was to be completed at least 
every 12 hours while the patient was in the PICU, and at least daily while in the hospital, 
from the day opioid weaning commenced until 72 hours after the patient received the last 
opioid dose. The highest daily WAT-1 score was used in analyses, with scores ≥3 being 
used as a validated cutoff for IWS from previous studies [20,26]. No recommendations 
were provided for patient management based on WAT-1 score during the baseline period. 
Weaning pattern: Line graphs illustrating daily opioid and benzodiazepine doses 
and WAT-1 scores over the study period were constructed for each patient (L.A.A). Two 
investigators (L.S.F. and M.A.Q.C.), blind to the clinical characteristics of each patient, 
independently reviewed each patient’s graph to make a preliminary determination 
regarding each patient’s weaning pattern. These observations were then used to construct 
a decision-making algorithm (K.M.B.) for verifying, assigning, or reassigning the 
patient’s clinician-reported start of opioid weaning (Figure 3-1). Assignment of the start 
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of opioid weaning was necessary for patients with missing data. In addition, the clinician-
reported start of opioid weaning may have been unreliable in cases where there was >2 
day difference between the start of weaning and the day of peak dose. The start of opioid 
weaning was reassigned if (1) the clinician-reported start of weaning occurred >2 days 
before a peak opioid dose and/or (2) methadone was started >2 days before the clinician-
reported start of weaning. 
Once a patient’s start of weaning was verified, a weaning pattern was assigned. 
An inconsistent pattern of weaning was assigned to those patients with an irregular 
pattern of weaning that included a 20% or greater increase in the total daily opioid dose at 
any time during the weaning period. A consistent pattern of weaning was assigned to the 
remaining patients.  
Data analysis: Descriptive statistics were calculated, including means, standard 
deviations, medians, and interquartile ranges for continuous variables, and frequency 
counts and percentages for categorical variables. Group comparisons were made between 
patients with an inconsistent weaning pattern and those with a consistent weaning pattern. 
Logistic, cumulative logit, linear, and proportional hazards regression, controlling for site 
as a cluster variable using generalized estimating equations, were used to analyze binary, 
ordinal, log-transformed continuous, and time-to-event variables, respectively. Analyses 
were performed using SAS (version 9.4, SAS Institute, Cary, NC) and R (version 3.1.1, 
The R Foundation for Statistical Computing, Vienna, Austria).  
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Results 
Patient characteristics: Of 308 patients enrolled in the baseline, pre-randomization 
phase of the RESTORE clinical trial, 186 patients experienced five or more consecutive 
days of opioid administration. An additional 36 patients were excluded because weaning 
was not complete by the end of the 28-day study period, one patient was lost to follow-up 
because of transfer to an outside institution, and four patients were non-survivors. The 
final sample included 145 patients.  
The median opioid start of weaning was 6 days (interquartile range [IQR]: 5-8 
days), and 66 patients (46%) were inconsistently weaned. The start of opioid weaning 
occurred later for patients with an inconsistent pattern of weaning compared to patients 
with a consistent pattern of weaning (median; IQR: Day 6; 5-9 vs Day 5; 5-7; P=0.006). 
Figure 3-2 illustrates graphs of representative patients with consistent and inconsistent 
patterns of weaning. 
Patient characteristics are shown in Table 3-1. There were no significant 
differences in baseline demographic or clinical characteristics between patients with 
inconsistent and consistent patterns of weaning. Patients with an inconsistent pattern of 
weaning experienced a longer duration of mechanical ventilation and PICU and hospital 
lengths of stay when compared to patients who were weaned consistently. Patients with 
an inconsistent pattern of weaning also had higher total cumulative opioid (median; IQR: 
35.7 mg/kg; 17.4-61.2 vs 16.5 mg/kg; 7.4-25.5; P<0.001) and benzodiazepine doses (28.3 
mg/kg; 11.2-65.0 vs 12.8 mg/kg; 5.7-22.2; P<0.001) than patients with a consistent 
pattern of weaning. 
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Preweaning exposure: Characteristics of opioid and benzodiazepine exposure in 
the preweaning period are shown in Table 3-2. The majority of patients in both groups 
received fentanyl and midazolam as their primary opioid and benzodiazepine agents. In 
the preweaning period, patients with an inconsistent pattern of weaning received higher 
preweaning daily peak and cumulative doses of opioids and benzodiazepines and had 
longer durations of exposure to opioids and benzodiazepines. Patients with an 
inconsistent weaning pattern were also more likely to have developed tolerance to 
opioids, and to have received a total midazolam dose >60 mg/kg prior to the start of 
weaning. Inconsistently weaned patients were more likely to have received chloral 
hydrate and barbiturates. There were no significant differences between groups in the 
number of patients receiving methadone, clonidine, dexmedetomidine, ketamine, or 
propofol prior to the start of opioid weaning.  
Exposure during weaning: Characteristics of opioid and benzodiazepine exposure 
during weaning are shown in Table 3-3. The percent decrease in daily opioid dose over 
the first 24 and 48 hours after the initiation of weaning was lower among patients with 
inconsistent patterns of weaning. Inconsistently weaned patients received more opioid 
boluses and received boluses for significantly more days during the weaning period. A 
greater proportion of patients with an inconsistent pattern of weaning received 
methadone, clonidine, dexmedetomidine, chloral hydrate, and barbiturates during the 
weaning period. One hundred twelve (77%) patients were assessed for withdrawal 
symptoms using the WAT-1. More patients with an inconsistent pattern of weaning had 
WAT-1 assessments performed during the weaning period, had WAT-1 scores ≥3, and 
had higher peak WAT-1 scores. Among patients with WAT-1 assessments, tolerance to 
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opioids was observed more frequently in patients who ever had WAT-1 scores ≥3, 
compared to patients who always scored <3 (37% vs 19%; P=0.02).  
Discussion 
This study is the first multicenter analysis of patterns of sedation weaning among 
children recovering from critical illness. We used a novel algorithm to identify the start 
of weaning with a graphical approach to plot changes in sedative dosing with 
corresponding withdrawal assessments for each patient, which allowed us to classify two 
patterns of weaning: consistent and inconsistent. The inconsistent weaning pattern was 
associated with higher (preweaning and overall) cumulative and peak doses and longer 
preweaning exposures of opioids and benzodiazepines, as well as longer lengths of 
hospital stay. Higher WAT-1 scores associated with IWS were also seen in inconsistently 
weaned patients with completed assessments. 
Our findings align with previous research, which showed that higher cumulative 
and peak doses of opioids and benzodiazepines and longer exposures are associated with 
IWS [6,10-13,16,20,28]. However, our data are the first to quantify their associations 
with an inconsistent weaning pattern. While intuitive, these findings suggest that current 
weaning practices should be more critically examined, not only for the rate of dose 
reductions but also for consistency. Of note, our two patterns of weaning could not be 
differentiated by previously published threshold doses of fentanyl that have been 
associated with IWS.  These published thresholds included sedative doses received after 
the start of weaning [6,10,11], a criterion that limits their prognostic utility for weaning 
outcomes.  
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In this study, more patients with an inconsistent pattern of weaning met criteria 
for opioid tolerance. Typically, the focus of opioid tolerance is placed on the escalation of 
sedation therapy and not necessarily on sedation weaning. Only one previous study 
reported using a standard definition of opioid tolerance when describing the weaning 
process [3], which was adapted for this analysis. Future studies can apply this easily 
computed definition of opioid tolerance, that is, a doubling of the Day 2 opioid dose to 
achieve the same therapeutic effect over the acute preweaning phase of illness, when 
planning how best to wean patients from sedation. 
During the first 24 and 48 hours of weaning, consistently weaned patients 
tolerated a greater percent drop in their daily opioid dose.  In addition, our data show 
wide variation in the percent drop experienced by patients during opioid weaning, even 
when unit-based weaning protocols were reported to be in place. Patients with an 
inconsistent pattern of weaning received significantly more opioid rescue bolus doses for 
a greater number of days during the weaning period, beginning with the day of the start 
of weaning. This result may indicate that signs of IWS were first observed soon after the 
start of weaning.  
Examination of WAT-1 scores showed that more inconsistently weaned patients 
with assessments had peak WAT-1 scores ≥3. It is interesting to note that patients with 
inconsistent patterns of weaning experienced greater frequency and severity of WAT-1 
scores despite receiving significantly more doses of methadone, clonidine, 
dexmedetomidine, chloral hydrate, and barbiturates during the weaning period.  
This study has some limitations, the most significant of which is that the findings 
cannot offer evidence for causation. The question of whether inconsistent weaning 
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patterns are the outcome of preweaning risk factors or a contributory cause of higher 
WAT-1 scores and more intensive or protracted weaning remains unanswered. In 
particular, not all patients were assessed for IWS, which may have caused an 
ascertainment bias in the observed association between inconsistent weaning and IWS. 
Without a complete picture of benzodiazepine weaning in this dataset or a definition of 
benzodiazepine tolerance, it is impossible to draw conclusions about tolerance to 
benzodiazepines among patients in this study. It is possible that patients became tolerant 
to both opioids and benzodiazepines, especially since more inconsistently weaned 
patients received preweaning benzodiazepine doses >60 mg/kg, a threshold associated 
with IWS [14]. As in previous studies [7,26], it is impossible to parse the effects of these 
medications, since most patients received both concurrently. Finally, the available data 
offers little insight into the clinical practices or environment in which children were 
undergoing recovery and weaning, or the effects of either sedation therapy or the 
environment on restorative sleep, both of which may have been contributory to increased 
sedative needs in certain patients [29,30]. These considerations will require further 
research.  
Conclusion 
This study provides further characterization of the clinical profiles of pediatric 
patients during weaning from sedatives after critical illness. Using baseline, pre-
intervention data allowed this study an unrestrained view of current practices in sedation 
management and weaning in PICUs of varying size and geographic location. Our 
findings suggest that weaning is consistent and uncomplicated among patients who 
receive lower preweaning medication doses and fewer days of sedative exposure. By 
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contrast, inconsistent weaning is associated with opioid tolerance and possibly worse 
clinical outcomes, including higher incidence and severity of withdrawal symptoms and 
longer lengths of stay. Further research is needed to improve the practice of opioid and 
benzodiazepine weaning in pediatric patients, which may be strengthened by the 
application of the methods and operational definitions described here. 
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Figures and Tables 
Figure 3-1. Start of weaning decision algorithm 
 
Note: The algorithm assigned the start of opioid weaning for 42 patients (29%) missing data on 
the clinician-reported start of weaning.  For the remaining 103 patients, the clinician-reported 
start of weaning was verified by the algorithm for 78 patients (76%) and reassigned for 25 
patients (24%). 
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Figure 3-2. Opioid weaning patterns 
 
Representative graphs of daily opioid and benzodiazepine doses among patients with consistent 
(A) and inconsistent (B) patterns of opioid weaning. Note: The first vertical line marks the day of 
the peak opioid dose, while the second vertical line represents the start of the opioid weaning 
period. 
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Table 3-1. Patient characteristics by pattern of weaning 
Variable Consistent 
Wean (N=79) 
Inconsistent 
Wean (N=66) 
P Valuea 
Baseline Characteristics    
Age at PICU admission    
  Median (IQR) – years 2.0 (0.4-8.3) 1.4 (0.3-4.9) 0.32 
  2 weeks to 1.99 years – no. (%) 40 (51) 37 (56) 0.16 
  2.00 to 5.99 years 11 (14) 15 (23)  
  6.00 to 17.99 years 28 (35) 14 (21)  
Female – no. (%) 45 (57) 33 (50) 0.49 
Non-Hispanic white – no./total no. (%) 45/76 (59) 43/64 (67) 0.52 
Baseline PCPC=1 – no. (%)b 62 (78) 48 (73) 0.28 
Baseline POPC=1 – no. (%)b 61 (77) 45 (68) 0.11 
Able to verbally communicate pain at baseline –  
  no./total no. (%)c 
 
31/44 (70) 
 
29/34 (85) 
 
<0.001 
PRISM III-12 score – median (IQR) 6 (2-12) 6 (3-12) 0.44 
Percent risk of mortality based on PRISM III-12  
  score – median (IQR) 
 
2 (1-12) 
 
3 (1-13) 
 
0.46 
Primary reason for intubation – no. (%)   0.58 
  Pneumonia 31 (39) 28 (42)  
  Bronchiolitis 23 (29) 16 (24)  
  Acute respiratory failure related to sepsis 6 (8) 7 (11)  
  Asthma or reactive airway disease 5 (6) 5 (8)  
  Aspiration pneumonia 4 (5) 1 (2)  
  Other 10 (13) 9 (14)  
PARDS based on Day 1 OI or OSI – no. (%)d   0.76 
  At risk (OI <4.0 or OSI <5.0) 28 (35) 23 (35)  
  Mild (OI 4.0-7.9 or OSI 5.0-7.4) 24 (30) 17 (26)  
  Moderate (OI 8.0-16.0 or OSI 7.5-12.3) 18 (23) 19 (29)  
  Severe (OI >16.0 or OSI >12.3) 9 (11) 7 (11)  
Neuromuscular blockade for the entire duration of  
  Days 0 to 2 – no. (%) 
 
3 (4) 
 
5 (8) 
 
0.40 
Any past medical history – no. (%)    
  Prematurity (<36 weeks post-menstrual age) 10 (13) 5 (8) 0.14 
  Asthma (prescribed bronchodilators or steroids) 12 (15) 10 (15) 0.96 
  Seizure disorder (prescribed anticonvulsants) 11 (14) 6 (9) 0.46 
  Neurologic/neuromuscular disorder which places  
    patient at risk for aspiration 
 
8 (10) 
 
7 (11) 
 
0.83 
  Cancer (current or past diagnosis) 1 (1) 5 (8) 0.03 
  Known chromosomal abnormality 3 (4) 4 (6) 0.52 
Hospital Course    
Duration of mechanical ventilation – days, median  
  (IQR) 
 
5.9 (4.7-8.2) 
9.1 (6.3-11.9)  
<0.001 
PICU length of stay – days, median (IQR) 9.3 (6.9-12.7) 12.8 (9.5-17.0) <0.001 
Hospital length of stay – days, median (IQR) 14 (10-20) 21.5 (16-26) <0.001 
 
IQR, interquartile range; OI, oxygenation index; OSI, oxygen saturation index; PARDS, pediatric 
acute respiratory distress syndrome; PCPC, Pediatric Cerebral Performance Category; PICU, 
pediatric intensive care unit; POPC, Pediatric Overall Performance Category; PRISM III-12, 
Pediatric Risk of Mortality III score from first 12 hours in the PICU. 
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a P values for the comparison of patients with consistent vs. inconsistent weaning patterns were 
calculated using linear, cumulative logit, logistic, and proportional hazards regression accounting 
for site as a cluster variable using generalized estimating equations for log-transformed 
continuous, ordinal, binary, and time-to-event variables, respectively. 
b PCPC and POPC range from 1 to 6, with higher categories indicating greater impairment. 
c Able to verbally communicate pain at baseline includes only patients aged 16 months and older. 
d Oxygenation index (OI) was calculated as [(FIO2 × mean airway pressure)/PaO2 × 100]. When 
an arterial blood gas was not available, SpO2 was used to estimate PaO2 in order to calculate 
oxygen saturation index (OSI) [(FIO2 × mean airway pressure)/SpO2 × 100]. Lower scores reflect 
better oxygenation. 
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Table 3-2. Opioid and benzodiazepine exposure pre-opioid weaning by pattern of 
weaning 
Variable Consistent  
Wean (N=79) 
Inconsistent 
Wean (N=66) 
P Valuea 
Primary opioid agent preweaning – no. (%)b   0.94c 
  Fentanyl 58 (73) 47 (71)  
  Morphine 21 (27) 18 (27)  
  Hydromorphone 0 1 (2)  
Opioid exposure preweaning – mg/kg, median  
  (IQR)d 
   
  Peak daily dose 3.4 (1.7-5.7) 5.0 (2.6-7.9) 0.006 
  Cumulative dose 13.4 (6.4-21.7) 19.8 (9.7-39.1) 0.004 
  Cumulative dose – morphine only 0.1 (0-1.3) 0.4 (0-2.6) 0.04 
  Cumulative dose – fentanyl only, mcg/kg 187.8 (3.1-319.0) 196.7 (16.2-433.4) 0.30 
  Exposure days – median (IQR) 5 (5-6) 6 (5-9) <0.001 
Primary benzodiazepine agent pre-opioid  
  weaning – no. (%)b,e 
  0.52f 
  Midazolam 59 (75) 51 (77)  
  Lorazepam 18 (23) 15 (23)  
  None 2 (3) 0  
Benzodiazepine exposure pre-opioid weaning 
– mg/kg, median (IQR)e 
   
  Peak daily dose 2.7 (1.5-4.9) 4.1 (1.6-7.3) 0.005 
  Cumulative dose 9.6 (4.6-17.6) 15.4 (6.1-38.5) <0.001 
  Exposure days – median (IQR) 5 (5-6) 6 (5-9) <0.001 
Tolerance    
  Doubling of Day 2 opioid dose pre-opioid  
    weaning – no. (%) 
 
19 (24) 
 
26 (39) 
 
0.01 
Thresholds pre-opioid weaning – no. (%)    
  Total fentanyl >2.5 mg/kg or >9 days11 6 (8) 9 (14) 0.33 
  Total fentanyl >1.6 mg/kg or >5 days13 23 (29) 27 (41) 0.14 
  Total fentanyl >1.2 mg/kg6 0 4 (6) 0.27 
  Total midazolam >60 mg/kge,14 0 11 (17) 0.005 
Other sedatives pre-opioid weaning – no. (%)    
  Methadone 6 (8) 10 (15) 0.09 
  Clonidine 0 1 (2) 1.0 
  Dexmedetomidine 12 (15) 16 (24) 0.17 
  Ketamine 11 (14) 10 (15) 0.92 
  Chloral hydrate 7 (9) 14 (21) 0.01 
  Propofol 10 (13) 3 (5) 0.11 
  Barbiturates 3 (4) 9 (14) 0.04 
Number of sedative classes received pre-opioid  
  weaning – median (IQR)g 
 
2 (2-3) 
 
2 (2-3) 
 
0.07 
  1 – no. (%) 2 (3) 0  
  2 46 (58) 34 (52)  
  3 22 (28) 18 (27)  
  4-7 9 (11) 14 (21)  
 
IQR, interquartile range. 
a P values for the comparison of patients with consistent vs. inconsistent weaning patterns were 
calculated using logistic, linear, and proportional hazards regression accounting for site as a 
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cluster variable using generalized estimating equations for binary, log-transformed continuous, 
and time-to-event variables, respectively. Where there was a zero count in the consistent wean 
group, the P value was calculated with the use of a stratified exact test with adjustment for site. 
b Primary opioid agent during the preweaning period was defined as the opioid administered via 
continuous infusion. If no opioid or more than one opioid was administered via continuous 
infusion, primary opioid agent was defined as the opioid administered on the highest number of 
study days. If fentanyl and morphine were administered on the same number of days, primary 
opioid agent was defined as the opioid contributing the highest morphine equivalents. Primary 
benzodiazepine during the pre-opioid weaning period was assigned similarly. If midazolam and 
lorazepam were administered on the same number of days, primary benzodiazepine agent was 
defined as the benzodiazepine contributing the highest midazolam equivalents. 
c This P value compares primary agent morphine vs. fentanyl. 
d Opioid doses were calculated as morphine equivalents in mg/kg. Opioids (morphine 
equivalents) include morphine (1), fentanyl (0.015), methadone (0.3), enteral codeine (20), 
hydromorphone (0.15), enteral oxycodone (3), and remifentanil (0.015). 
e Benzodiazepine data was collected until study discharge, which was based on the end of opioid 
exposure; thus patients may have still been receiving benzodiazepines at study discharge. 
Benzodiazepine doses were calculated as midazolam equivalents in mg/kg. Benzodiazepines 
(midazolam equivalents) include midazolam (1), clonazepam (0.2), lorazepam (0.3), and 
diazepam (2). Excludes 9 patients (6 consistent, 3 inconsistent) who did not wean from 
benzodiazepines. 
f This P value compares primary agent midazolam vs. lorazepam. 
g Different sedative classes include opioids, benzodiazepines, alpha2-adrenergic agonists, 
ketamine, chloral hydrate, propofol, and barbiturates.  
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Table 3-3. Opioid and benzodiazepine exposure during opioid weaning by pattern of 
weaning 
Variable Consistent  
Wean (N=79) 
Inconsistent 
Wean (N=66) 
P Valuea 
Opioid exposure during weaning – mg/kg,  
  median (IQR) 
   
  Peak daily doseb 0.9 (0.1-2.7) 3.0 (1.0-5.6) <0.001 
  Cumulative doseb 1.5 (0.1-4.3) 11.5 (3.9-19.9) <0.001 
  Exposure days – median (IQR) 2 (1-5) 10.5 (8-13) <0.001 
Benzodiazepine exposure during opioid weaning  
  – mg/kg, median (IQR) 
   
  Peak daily dosec 1.1 (0.1-2.6) 2.3 (1.2-5.5) <0.001 
  Cumulative dosec 1.5 (0.3-4.5) 9.0 (2.7-19.6) <0.001 
Percent drop in daily opioid dose from start of  
  wean to next day – median (IQR)d 
 
47 (0-100) 
 
24 (–10-57) 
 
<0.001 
Percent drop in daily opioid dose from start of  
  wean to 2 days later – median (IQR)d 
 
82 (13-100) 
 
42 (–2-81) 
 
0.02 
Received opioid bolus doses during weaning –  
  no. (%) 
 
50 (63) 
 
57 (86) 
 
0.003 
  Number of days patient received opioid bolus  
    doses – median (IQR) 
 
1 (1-2) 
 
3 (2-5) 
 
<0.001 
Other sedatives during opioid weaning – no. 
(%)e 
   
  Methadone 15 (19) 37 (56) <0.001 
  Clonidine 1 (1) 8 (12) 0.004 
  Dexmedetomidine 14 (18) 23 (35) 0.002 
  Ketamine 4 (5) 5 (8) 0.64 
  Chloral hydrate 3 (4) 7 (11) 0.04 
  Propofol 6 (8) 7 (11) 0.64 
  Barbiturates 2 (3) 6 (9) 0.002 
Number of sedative classes received during  
  opioid weaning – median (IQR) 
 
2 (1-3) 
 
2 (2-3) 
 
<0.001 
  0, no. (%) 7 (9) 0  
  1 13 (16) 4 (6)  
  2 39 (49) 31 (47)  
  3 14 (18) 16 (24)  
  4-7 6 (8) 15 (23)  
WAT-1 assessments performed during opioid  
  weaning – no. (%) 
 
50 (63) 
 
62 (94) 
 
<0.001 
  WAT-1 ever ≥ 3 – no./total no. (%) 23/50 (46) 53/62 (85) <0.001 
  Peak WAT-1 score – median (IQR) 2 (1-5) 5 (4-6) <0.001 
 
IQR, interquartile range; WAT-1, Withdrawal Assessment Tool – Version 1. 
a P values for the comparison of patients with consistent vs. inconsistent weaning patterns were 
calculated using linear, proportional hazards, and logistic regression accounting for site as a 
cluster variable using generalized estimating equations for log-transformed continuous, time-to-
event, and binary variables, respectively. Percent drop variables were not log-transformed due to 
negative values. 
b Opioid doses were calculated as morphine equivalents in mg/kg. Opioids (morphine 
equivalents) include morphine (1), fentanyl (0.015), methadone (0.3), enteral codeine (20), 
hydromorphone (0.15), enteral oxycodone (3), and remifentanil (0.015). 
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c Benzodiazepine data was collected until study discharge, which was based on the end of opioid 
exposure; thus patients may have still been receiving benzodiazepines at study discharge. 
Benzodiazepine doses were calculated as midazolam equivalents in mg/kg. Benzodiazepines 
(midazolam equivalents) include midazolam (1), clonazepam (0.2), lorazepam (0.3), and 
diazepam (2).  
d Excludes 2 consistently weaned patients who started weaning on day 5 and were study 
discharged that day. 
e Different sedative classes include opioids, benzodiazepines, alpha2-adrenergic agonists, 
ketamine, chloral hydrate, propofol, and barbiturates. 
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CHAPTER 4 
A PREDICTIVE MODEL OF RISK FOR IATROGENIC WITHDRAWAL 
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Running head: Prediction of IWS risk in critically ill children 
 
Subject category: 4.11 (Pediatric Critical Care) 
 
At a Glance Commentary: We provide new evidence for younger age, pre-existing 
cognitive impairment and higher nursing workload as risk factors for iatrogenic 
withdrawal syndrome, as well as confirming previously identified associations with dose 
and duration of sedative exposure. As the largest study of iatrogenic withdrawal 
syndrome in critically ill children to date, this is also the first study to characterize 
system-level influences on this outcome. The identified risk factors could inform future 
practice in sedation management and weaning. 
 
This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org.
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Abstract 
Rationale: Sedation use in pediatric critical illness is associated with iatrogenic 
withdrawal syndrome during recovery. Little is known about risk factors for iatrogenic 
withdrawal beyond sedative dose and exposure time. 
Objectives: To create a predictive model of patient, process and system risk factors for 
iatrogenic withdrawal in critically ill pediatric patients who received ≥5 days of sedation. 
Methods: Secondary analysis of prospective data from a clinical trial of nurse-led, goal-
directed sedation management. Logistic regression with generalized estimating equations 
to account for clustering by site was used to evaluate risk factors for iatrogenic 
withdrawal. 
Measurements and Main Results: Iatrogenic withdrawal was defined as having at least 
two Withdrawal Assessment Tool-1 scores ≥3 after the start of opioid weaning. Eligible 
subjects with iatrogenic withdrawal (544/1157; 47%) were younger and more likely to 
have pre-existing cognitive or functional impairment. Subjects with iatrogenic 
withdrawal received higher sedative doses and longer exposure periods. In multivariable 
analyses, significant predictors of iatrogenic withdrawal included younger age (OR 2.73, 
p<0.001), pre-existing cognitive impairment (OR 1.98, p<0.001), higher preweaning 
mean daily opioid dose (OR 1.39, p<0.001), longer duration of sedation (OR 1.07, 
p=0.046), receipt of three or more preweaning sedative classes (OR 1.39, p<0.001), 
higher nursing workload (OR 1.68, p=0.004) and receiving care at sites with higher 
proportions of 1:1 nurse staffing (OR 1.15, p=0.002). 
Conclusions: Iatrogenic withdrawal syndrome is common in children recovering from 
critical illness and several risk factors are predictive. High-risk patients could be 
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identified before starting weaning to better prevent iatrogenic withdrawal among at-risk 
patients.  
Key words: Opioid; benzodiazepine; sedation; WAT-1; RESTORE  
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Introduction 
Although opioids and benzodiazepines are routinely used to achieve analgesia and 
sedation in critically ill pediatric patients, they may also cause untoward effects. In 
particular, iatrogenic withdrawal syndrome (IWS) can cause discomfort for patients, 
increased sedation exposure and prolonged duration of mechanical ventilation and 
lengths of stay.1,2 IWS is a constellation of signs and symptoms spanning three 
physiologic domains – autonomic dysfunction, gastrointestinal disturbances and 
neurologic and motor abnormalities – that manifest following rapid weaning or abrupt 
cessation of sedation therapy in physically dependent patients.1,3,4 Up to 57% of critically 
ill children in the pediatric intensive care unit (PICU) who receive opioids or 
benzodiazepines may exhibit signs and symptoms of IWS,5–7 a figure that increased to 
nearly 80% in a cohort of infants who had undergone extracorporeal membrane 
oxygenation (ECMO) or cardiac surgery.8 
To date, the majority of research on IWS has focused on characterizing its signs 
and symptoms3,4,9,10 and elucidating its association with threshold sedative 
exposures,5,7,11–14 such as duration of opioid or benzodiazepine therapy exceeding five 
days7,13 and cumulative doses greater than 1.6 mg/kg of fentanyl5,7 or 60 mg/kg of 
midazolam.14 Yet a clinical profile of the patient at risk for IWS is still lacking. Most 
previous studies have been limited by single center, retrospective designs and/or small 
samples. Younger12,15,16 or female15 patients with a greater severity of illness,15 including 
neurologic involvement,17,18 may be more likely to experience IWS. However, these 
findings have been inconsistent across published reports,19,20 at least in part due to a lack 
of standardization in defining and assessing IWS.21  
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Sedation management in the PICU occurs within a unique context that may also 
influence the development of IWS; however, little research has evaluated the process of 
sedation therapy or system-level determinants of related outcomes. For example, 
although most clinicians recognize the need to gradually wean patients from sedation 
therapy in order to prevent IWS,22,23 variation exists in the medications and doses used 
during sedation and weaning.12,24,25 Adherence to standardized sedation protocols 
including weaning algorithms and assessments for IWS is less than ideal,26,27 which may 
be a consequence of clinician factors27–30 or workflow constraints in busy PICUs.31 Little 
is known about system-level factors that may prevent the development of IWS in 
critically ill children. 
These gaps have resulted in a limited understanding of why children continue to 
experience IWS despite the implementation of protocols to prevent it.6,17,26,32 We have 
proposed a conceptual model illustrating the potential contributions of different levels of 
risk factors that impact a critically ill child’s risk for experiencing IWS during recovery 
in the PICU.21 The purpose of this study was to apply this framework in generating a 
predictive model of risk factors for IWS at the levels of the patient, the process and the 
healthcare system. A comprehensive profile of the at-risk patient may enable primary 
prevention of this iatrogenic complication, including potential restructuring of processes 
and systems of care in order to optimize sedation therapy for children in the PICU. 
Methods 
Data source: This study was a secondary analysis of data from the Randomized 
Evaluation of Sedation Titration fOr Respiratory FailurE (RESTORE) clinical trial. 
RESTORE was a multicenter cluster randomized trial testing the impact of a nurse-led, 
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goal-directed sedation management protocol on length of mechanical ventilation in 
critically ill pediatric patients with acute respiratory failure.6 Subjects were enrolled at 31 
sites from June 2009 to December 2013. Consent for prospective data collection was 
obtained from the subjects’ parents and/or legal guardians, and the institutional review 
board at each site approved the RESTORE study protocol.  
Study population: Patients aged 2 weeks (≥42 weeks postmenstrual age) to 17 
years were enrolled in the RESTORE trial if they were intubated and mechanically 
ventilated for acute respiratory failure. Detailed inclusion and exclusion criteria are 
published elsewhere.6 Eligible subjects for this secondary analysis included subjects from 
both the control and intervention groups who had ≥5 consecutive days of opioid exposure 
from continuous infusions, scheduled intermittent or as needed bolus doses. We excluded 
subjects who did not complete their course of sedative weaning within 28 days (i.e., non-
survivors, transfers and study withdrawals).  
Variables and measures: The primary outcome of IWS was defined as two or 
more Withdrawal Assessment Tool-1 (WAT-1) scores ≥3 after the start of opioid 
weaning. The WAT-1 is an 11-item (12-point) instrument that screens for signs and 
symptoms of opioid- and benzodiazepine-related IWS.4,9 Per protocol, subjects with ≥5 
days of opioid therapy were assessed at least twice daily in the PICU, and at least daily 
while in the hospital, from the start of opioid weaning until 72 hours after the last opioid 
dose. A one-time WAT-1 score ≥3 has excellent sensitivity (87%) and specificity (88%) 
for detection of IWS.4 Requiring more than one WAT-1 score ≥3 was a conservative 
approach to avoid inclusion of false positives from subjects with isolated symptoms 
unrelated to IWS. 
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Data were collected daily from endotracheal intubation (Day 0) until 72 hours 
after the last opioid dose, hospital discharge or Day 28 (whichever occurred first). 
Medication data included daily dose and route of all sedative medications, until the start 
of opioid weaning. Patient- and process-level variables were defined as in the primary 
publication6 or according to operational definitions included in the online supplement. 
System-level variables were drawn from each site’s self-reported pre-randomization 
organizational assessment and the case report forms from each enrolled subject. Each 
subject was assigned values for the system-level variables from their site, with the 
exception of nursing workload. The Nine Equivalents of nursing Manpower use Score 
(NEMS)33 was calculated daily for each patient; possible scores ranged from 0 to 56, with 
higher scores representing increasing nursing workload. Median preweaning scores 
calculated for each subject were used for analysis.  
Analysis: Subjects meeting eligibility criteria were dichotomized based on WAT-
1 scores. Potential predictors of interest (Supplemental Table 4-5) were explored for 
differences between groups. Variance within and between centers was accounted for 
using generalized estimating equations with an independent working correlation structure 
and robust sandwich variance estimator. Site-level variables were weighted by the inverse 
variance of each site’s IWS rate, then Pearson correlations (for continuous predictors) 
and linear regressions (for binary predictors) were used to evaluate associations with the 
proportion of subjects with IWS. Log-transformations were used as necessary for non-
normally distributed variables. An a priori threshold of p <0.2 was set for variables from 
bivariate analyses to be considered in the next stage of analysis. Multivariable logistic 
regression for model building used manual backward selection procedures and included 
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generalized estimating equations to account for clustering by site. Variables with p <0.05 
were retained. It was anticipated that several variables would be highly correlated (e.g., 
medication dose and duration); therefore, assessment of collinearity using rank-order 
Spearman correlations (rs) was included in the modeling strategy. All analyses were 
conducted using Stata version 13 (Stata LP, College Station, TX). 
Results 
Of 2449 enrolled subjects from the RESTORE study cohort, 1170 subjects (48%) 
were excluded due to receiving <5 consecutive days of opioid exposure (n=767), 
incomplete sedative weaning by Day 28 (n=309), transfer (n=19) and death or redirection 
of care (n=75). Of the 1279 remaining subjects, an additional 122 subjects (10%) were 
excluded because they did not have any WAT-1 assessments, leaving 1157 subjects for 
this analysis.  
IWS was observed in 544 subjects (47%) distributed across 31 sites, although 
there was a wide range in IWS rates per site (range 20%-80%). The intraclass correlation 
coefficient (ICC) of IWS was 0.051 (95% CI 0.026-0.142) after adjusting for age group, 
severity of illness (i.e., Pediatric Risk of Mortality [PRISM] III-12 score) and baseline 
functional status (i.e., Pediatric Overall Performance Category [POPC] score). Subjects 
with IWS were younger and more likely to have pre-existing cognitive and functional 
impairment (Table 4-1). There was no difference in the proportion of subjects with IWS 
between the control and intervention arms. 
Patient-level variables: Dose and duration of both opioid and benzodiazepine 
therapy were greater among subjects with IWS (Table 4-2). There was no difference in 
the incidence of IWS based on primary opioid or benzodiazepine agent used for sedation. 
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Opioid tolerance occurred more often in subjects with IWS. There were significant age-
related differences in both mean daily opioid and benzodiazepine dose (p<0.001 for 
each), with infants less than six months of age and children over six years receiving lower 
doses per kilogram regardless of IWS outcome (Figure 4-1). Age-related differences 
were not observed in sedative duration (p=0.20).  
Process-level variables: Patients with IWS tended to receive more classes of 
sedative medications prior to the start of weaning (Table 4-2) and were more likely to be 
inconsistently weaned (43% versus 26%, p≤0.001). Preweaning SBS assessment 
compliance was comparable between IWS and non-IWS subjects [median (interquartile 
range [IQR]): 86% (63-100) versus 80% (60-100); p=0.66].  
System-level variables: Few PICU characteristics were significantly correlated 
with the rate of IWS per site (Table 4-3). Median NEMS scores were 27 (IQR 27-34) 
among subjects with IWS and 27 (IQR 27-33) in non-IWS subjects (p=0.07). Nurse to 
patient staffing ratios were moderately correlated with the rate of IWS, suggesting higher 
rates of IWS in PICUs with a greater proportion of one nurse to one patient assignments. 
Regardless of IWS outcome, lower cumulative opioid doses were administered to patients 
treated in PICUs with a greater proportion of one-to-one assignments compared to sites 
with a lower frequency of high staffing ratios, even after adjusting for average patient 
age, severity of illness, nursing workload and number of annual PICU admissions 
(p<0.001).  
Collinear variables: Among the preweaning medication variables, cumulative 
opioid dose was strongly correlated with mean (rs=0.93, p<0.001) and peak (rs=0.90, 
p<0.001) daily opioid doses and with duration of sedative exposure (rs=0.93, p<0.001). 
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Benzodiazepine variables showed similar relationships. Baseline PCPC and POPC scores 
were also strongly correlated (rs=0.89, p<0.001). In order to build a parsimonious and 
valid model, we restricted consideration to preweaning duration of sedative exposure, 
preweaning mean daily opioid dose and pre-existing cognitive impairment in 
multivariable modeling. 
Multivariable modeling: The multivariable prediction model identified variables 
at the patient-, process- and system-levels with significant associations with IWS (Table 
4-4). Each additional day of sedative exposure increased a subject’s odds of experiencing 
IWS. Subjects under six months of age had the highest odds of experiencing IWS 
compared to the oldest age group. Pre-existing cognitive impairment nearly doubled the 
odds of IWS. Process- and system-level risk factors included receiving additional 
sedative medications beyond an opioid and benzodiazepine, higher preweaning NEMS 
scores and more one-to-one nurse staffing. The c-statistic for the model including only 
variables with individual patient-level data was 0.63 (95% CI 0.60-0.66), which slightly 
improved to 0.65 (95% CI 0.62-0.68) with the addition of the system-level variable. 
Although a greater number of subjects with IWS developed tolerance compared to the 
non-IWS group, that variable did not add to the predictive ability of the multivariable 
model after adjusting for medication characteristics, such as duration of sedative 
exposure.  
Discussion 
This study is the largest analysis of risk factors for IWS to date and the first to 
characterize contextual influences at the system level. In addition to confirming 
previously observed associations among dose and duration of sedative therapy and 
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IWS,2,5,7,11,13,14,34 we have provided new evidence for risk factors related to age, pre-
existing cognitive impairment and nursing workload. The risk factors identified in this 
study could inform future practice in sedation management. 
Infants under six months of age had the highest risk of experiencing IWS relative 
to other age groups. Previous studies have either been limited to specific age groups2,5,7,11 
or were underpowered to show an association between age and IWS.8,12,34 Altered 
pharmacokinetic profiles for sedative medications administered to neonates and infants 
are related to immature enzymatic pathways.35 Morphine clearance is lower in infants 
under six months regardless of hepatic or renal function, resulting in higher serum 
concentrations and longer half-lives.36 Midazolam exhibits similar patterns of age-
dependent reductions in metabolism.37 Our results show lower preweaning mean daily 
doses for both opioids and benzodiazepines among infants under six months, suggesting 
that adequate sedation was achieved at lower doses. The extended bioavailability of 
sedative medications in these patients may translate into prolonged receptor occupancy, 
which has been implicated as a mechanism for tolerance and physical dependence.38,39 
Despite the probable physiologic basis for these findings, it is possible that the observed 
differences in IWS risk based on age are an artifact of the measurement approach: our 
assessment tool (i.e., the WAT-1) demonstrated age-related variations in IWS symptom 
presentation during initial validation.4,9 Additional research in all age groups with 
measurement of plasma medication levels and/or clearance is recommended for further 
exploration. 
The etiology of our subjects’ pre-existing cognitive impairment is unknown. 
There is growing evidence for altered neurotransmitter function in the brains of children 
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with neurodevelopmental disorders causing cognitive impairments, including aberrant γ-
aminobutyric acid (GABA) signaling40 and differing levels of endogenous opioid 
production.44 Prolonged sedative administration may exacerbate existing imbalances in 
inhibitory and excitatory neurotransmission in these children, with unknown 
consequences when medication administration ceases. Our data suggest an increased risk 
for IWS in children with pre-existing cognitive impairment, which may or may not be 
related to neurochemically-based differences in medication response. The role of pre-
existing cognitive impairment is especially challenging to interpret given the frequent 
exclusion of children with neurologic disorders from studies of IWS.3,8,13,19 The 
performance of the WAT-1 in discriminating between symptoms of IWS and behavioral 
manifestations of cognitive impairment is also relatively unknown, although cognitively 
impaired children were in the validation sample.9 As long as sedation management for 
children with cognitive impairments continues to rely on opioid and benzodiazepine 
therapy, the potential risk for additional iatrogenic injury in this sub-population requires 
investigation.  
The contribution of severity of illness to patient risk for IWS is still unclear: 
although neither PRISM III-12 scores nor preweaning number of organ systems in failure 
were retained as predictors, NEMS scores are calculated from several items related to a 
patient’s criticality.33 The PRISM III-12 only captures severity of illness at admission and 
may not account for changes over the course of the PICU stay, reflected in its poorer 
performance in predicting mortality for patients with PICU stays over six days.42 There 
were too few renal and hepatic failure events for their contribution to IWS to be fully 
examined. Systemic inflammation and cytokine release associated with critical illness 
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have been found to decrease cytochrome P450 enzyme activity and midazolam 
clearance,43 thereby increasing plasma drug levels and suggesting a possible physiologic 
explanation for increased risk for IWS among sicker patients.44 However, the 
pharmacodynamic effect of these changes is unknown.  
Though criticality may have contributed to higher NEMS scores and their 
association with IWS, the potential effects of nursing workload should also be 
acknowledged. The use of system-level data makes it impossible to know the frequency 
or degree to which individual patients with IWS experienced either conditions of greater 
nursing workload or high nurse staffing ratios. However, higher nursing workload has 
been associated with more adverse patient outcomes, such as mortality.45 There may be a 
critical point at which high nursing workload increases the likelihood of adverse events.46 
In contrast, allocating a greater proportion of nurse staffing to one-to-one patient 
assignments is generally associated with lower risk of complications.47 The observed 
increase in IWS rates with more frequent one-to-one nurse staffing may reflect an 
ascertainment bias rather than a true effect on IWS risk; units where more nurses spent 
their entire shift with one patient may have more successfully identified early signs and 
symptoms of IWS. The observation that units reporting more frequent one-to-one 
assignments also tended to administer lower cumulative doses of opioids may add 
support to this hypothesis. That is, with nurses spending more of their time at the bedside, 
patients were adequately sedated at lower medication doses. These interpretations should 
be viewed with caution pending prospective exploration with patient-level data. 
This model’s predictive performance was lower than expected, but this finding is 
consistent with results from a previous study testing peak benzodiazepine dose as a risk 
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factor for IWS (AUC 0.67, 95% CI not reported).34 A different multivariate predictive 
model of IWS had better performance (AUC 0.83, 95% CI 0.75-0.92),10 but neither study 
corrected for model overfitting and minimal data on validity were provided. Thus, our 
ability to accurately predict the outcome of IWS based on clinical factors is still 
unknown, and this study is the first to suggest that system-level variables may also have 
an effect on IWS outcome. Currently available assessment tools were designed to 
measure both opioid- and benzodiazepine-related IWS.9,25 The maximal sensitivity and 
specificity of predictive models based on either instrument may be limited by different 
risk profiles for each phenomenon. 
This secondary analysis has limitations. First, WAT-1 assessments were not 
completed in all patients with ≥5 days of sedative exposure. It is possible that restricting 
analysis to the subset of patients with WAT-1 scores introduced selection bias, and the 
results of this analysis are not generalizable to patients with <5 days of sedative exposure. 
The outcome definition of two WAT-1 scores ≥3 has not been used previously, though it 
is based on well-established cutoffs.4,9 We considered this definition to be a conservative 
approach to quantifying IWS and reducing potential false positives from unrelated 
conditions. Subjects with only one WAT-1 ≥3 were assigned to the non-IWS group, but 
any resulting misclassification would be expected to bias the results toward the null. 
Finally, while this study identified associations between IWS and several risk factors, it 
did not provide causal evidence. Additional mechanistic studies are needed. The 
proposed model should be validated using an independent dataset, particularly for 
system-level factors collected for individual patients.  
 
107 
In conclusion, IWS is a common complication among pediatric patients 
recovering from critical illness. We explored the relative contributions of a number of 
IWS risk factors aside from sedative dose and duration, which offer several avenues for 
future investigation. Predictive modeling suggests that younger patients and those with 
pre-existing cognitive impairments are at increased risk for IWS, along with patients who 
experience higher mean daily opioid doses, longer exposure periods or receive more 
classes of sedative medications. Inclusion of additional process and system factors 
provided a novel contribution to the literature. With further prospective validation, the 
identified risk factors could be used to inform individualized approaches to sedation 
practice in these critically ill patients, including IWS risk assessments. 	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Figures and Tables 
Figure 4-1. Mean daily sedation dose preweaning according to age category and IWS 
status 
Note: Box plots present median (IQR) for each dose by age category, with outlying values (two 
outliers excluded from mean daily opioid dose preweaning plot) 
A.	  Opioid	  dose	  
B.	  Benzodiazepine	  dose	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Table 4-1. Demographic and clinical characteristics of study sample according to IWS 
status 
Characteristicsa IWS  
(n=544) 
Non-IWS  
(n=613) 
P Value 
Age at PICU admission    
   Median (IQR) – years  1.1 (0.3-4.4) 1.6 (0.3-6.6) 0.01 
   2 weeks to 6 months 207 (38) 197 (32) 0.06 
   6 months to 1.99 years 133 (24) 141 (23)  
   2.00 to 5.99 years  96 (18) 108 (18)  
   6.00 to 17.99 years 108 (20) 167 (27)  
Female 239 (44) 282 (46) 0.50 
Non-Hispanic white, n/total n (%) 292/542 (54) 287/607 (47) 0.05 
Cognitive impairment (baseline PCPC >1)b 134 (25) 110 (18) 0.003 
Functional impairment (baseline POPC >1)b 157 (29) 137 (22) 0.01 
PRISM III-12 score 7 (3-12) 6 (3-11) 0.26 
Risk of mortality based on PRISM III-12 score, % 3.8 (1.0-11.7) 2.9 (1.0-9.5) 0.14 
Organ dysfunction preweaning    
   Cardiovascular 259 (48) 273 (45) 0.25 
   Neurological 254 (47) 273 (45) 0.60 
   Hematological 107 (20) 97 (16) 0.12 
   Hepatic 91 (17) 93 (15) 0.44 
   Renal 36 (7) 29 (5) 0.17 
No. of failed organ systems preweaning 2 (1-3) 2 (1-3) 0.11 
Preweaning ECMO support 11 (2) 6 (1) 0.08 
RESTORE intervention 315 (58) 345 (56) 0.76 
 
Abbreviations: ECMO – extracorporeal membrane oxygenation; IQR – interquartile range; IWS – 
iatrogenic withdrawal syndrome; PCPC – Pediatric Cerebral Performance Category; PICU – 
pediatric intensive care unit; POPC – Pediatric Overall Performance Category; PRISM III-12 – 
Pediatric Risk of Mortality III score from first 12 hours in the PICU 
a Data are median (interquartile range) or number (%) unless otherwise specified 
b PCPC and POPC scores range from 1 to 6, with higher categories indicating greater impairment 
(Fiser et al., 1992)48 
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Table 4-2. Preweaning medication characteristics according to IWS status 
Characteristicsa IWS  
(n=544) 
Non-IWS  
(n=613) 
P Value 
Primary opioid preweaning   0.68 
Morphine 223 (41) 259 (42)  
Fentanyl 321 (59) 351 (57)  
Hydromorphone or remifentanil 0 (0) 3 (0.5)  
Primary benzodiazepine preweaning   0.29 
Midazolam 481 (88) 515 (84)  
Lorazepam 60 (11) 94 (15)  
None 3 (0.6) 4 (0.7)  
Opioid exposure preweaningb – in mg/kg    
   Mean daily dose 2.9 (1.8-4.5) 2.6 (1.4-4.0) <0.001 
   Peak daily dose 4.5 (2.8-7.7) 3.9 (2.2-6.3) <0.001 
   Cumulative dose 19.1 (11.1-34.1) 15.7 (8.1-26.9) <0.001 
Benzodiazepine exposure preweaningb – in mg/kg    
   Mean daily dose 2.5 (1.4-4.2) 2.1 (1.1-3.7) 0.001 
   Peak daily dose 3.8 (2.3-7.1) 3.2 (1.8-6.4) 0.001 
   Cumulative dose 16.0 (8.5-31.5) 12.3 (6.6-25.2) <0.001 
No. days of sedation exposure (opioid and/or 
benzodiazepine) 
6 (5-8) 6 (5-7) <0.001 
Tolerance 
   Doubling of Day 2 opioid dose preweaning 
157 (29) 130 (21) 0.004 
No. of sedative classes received preweaning  3 (2-4) 3 (2-3) 0.03 
   <3  228 (42) 298 (49) 0.01 
   ≤3 316 (58) 315 (51)  
 
Abbreviations: IWS – iatrogenic withdrawal syndrome 
a Data are median (interquartile range) or number (%) unless otherwise specified 
b For group comparisons, continuous opioid and benzodiazepine dose variables were log-
transformed to approximately normalize the variables 
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Table 4-3. System-level characteristics of study sample and associations with site-
specific IWS rate 
Continuous characteristics Overalla 
(n = 31) 
Correlationb P value 
PICU beds  22 (16-29) -0.18 0.35 
Mean daily census  15 (11-19) -0.05 0.81 
Annual admissions  1116 (792-1827) 0.07 0.70 
No. PICU attending physicians  9 (7-10) -0.10 0.59 
No. PICU nurses  69 (47-97) 0.04 0.82 
Percent staffing that is 1 nurse:1 patient  30 (20-50) 0.34 0.06 
Percent with BSNc  80 (74-90) 
 
-0.27 0.18 
Binary characteristics 
Sites with 
characteristic 
Sites without 
characteristic P value 
 N Rated N Rated  
Medical management: Open PICU  20 49 (3) 11 42 (4) 0.26 
ANCC Magnet Recognition®  15 45 (3) 16 49 (4) 0.46 
Professional advancement program for nurses  24 46 (3) 7 51 (7) 0.46 
Unit-based pharmacist participates in rounds  26 48 (3) 5 40 (11) 0.30 
 
Abbreviations: ANCC – American Nurses Credentialing Center; BSN – Bachelor’s of Science in 
Nursing; IQR – interquartile range; IWS – iatrogenic withdrawal syndrome; PICU – pediatric 
intensive care unit; SBS – State Behavior Scale 
a Reported values are median (IQR) 
b Pearson’s correlations were calculated using analytic weights based on the inverse variance of 
the rate of IWS by site for continuous predictors 
c Calculated correlation based on data from 29 sites 
d Reported values are mean (SE) proportion of subjects with IWS weighted by the inverse 
variance of the rate of IWS by site 
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Table 4-4. Predictive models of IWS 
   
Predictor Variables Variables collected by 
subject only 
Variables collected by 
subject and by PICU 
Patient-level 
Adjusted ORs 
(95% CI) 
P value Adjusted ORs 
(95% CI) 
P value 
Age category     
2 weeks to 6 months 2.63 (1.65-4.21) <0.001 2.73 (1.69-4.42) <0.001 
6 months to 1.99 years 1.62 (1.08-2.43) 0.02 1.55 (1.03-2.34) 0.04 
2.00 to 5.99 years 1.32 (0.89-1.96) 0.16 1.20 (0.82-1.77) 0.34 
6.00 to 17.99 years Ref -- Ref -- 
Cognitive impairment (baseline PCPC >1) 1.87 (1.34-2.59) <0.001 1.98 (1.41-2.78) <0.001 
Duration of sedative exposure preweaning 1.07 (1.01-1.13) 0.03 1.07 (1.00-1.14) 0.046 
Mean daily opioid dose preweaninga 1.25 (1.00-1.57) 0.053 1.39 (1.16-1.67) <0.001 
 
Process-level     
No. of preweaning sedative classes ≥ 3 1.34 (1.01-1.79) 0.045 1.39 (1.04-1.87) 0.03 
 
System-level     
Median preweaning NEMS scoreb 1.62 (1.12-2.34) 0.01 1.68 (1.18-2.40) 0.004 
Pct. of staffing 1 RN: 1 patientc -- -- 1.15 (1.05-1.25) 0.002 
 
Abbreviations: NEMS – Nine Equivalents of nursing Manpower use Score; OR – odds ratio; 
PCPC – Pediatric Cerebral Performance Category; RN – registered nurse 
a Odds ratio reported for change from 25th to 75th percentile of log-transformed mean daily opioid 
dose 
b Odds ratio reported for a 10-unit change in NEMS score 
c Odds ratio reported for a 10% change in value 
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Supplemental Methods 
Variables and measures: Medication data included cumulative, mean, and peak 
daily opioid dosage (in morphine equivalents per kg of body weight), cumulative, mean, 
and peak daily benzodiazepine dosage (in midazolam equivalents per kg of body weight), 
and administration of any other sedative medications (e.g., chloral hydrate, clonidine, 
dexmedetomidine, ketamine, pentobarbital, phenobarbital, and propofol), all collected to 
the start of opioid weaning. Daily and cumulative sedative medication doses were 
compared using standard equivalencies.1 Specifically, morphine equivalent conversion 
factors to equal 1 mg morphine sulfate were as follows: 15 µg remifentanil; 15 µg 
fentanyl; 0.15 mg hydromorphone; and 0.3 mg methadone. Midazolam equivalent 
conversion factors to equal 1 mg midazolam were: 0.2 mg clonazepam; 0.3 mg 
lorazepam; and 2 mg diazepam. A composite variable for duration of sedation was 
created, reflecting days where either opioids or benzodiazepines were administered in the 
preweaning period. The start of opioid weaning was reported by the clinician and verified 
or reassigned according to a standard algorithm. Tolerance to opioids was defined as a 
doubling of the Day 2 opioid dose prior to the start of weaning. An inconsistent pattern of 
weaning was assigned to subjects with a course of weaning that included ≥20% increases 
in total daily opioid doses at any time after the start of opioid weaning. 
Patient-level demographic and clinical data included age, gender, race/ethnicity, 
severity of illness and mortality risk (Pediatric Risk of Mortality (PRISM) III-12),2 and 
need for ECMO in the preweaning period. Subjects were considered to have a pre-
existing cognitive or functional impairment if their Pediatric Cerebral Performance 
Category (PCPC) and Pediatric Overall Performance Category (POPC)3 scores were >1, 
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respectively. Each subject was evaluated for the presence of acute organ dysfunction 
prior to the start of opioid weaning based on daily lab values and other clinical data.4 All 
RESTORE subjects had respiratory dysfunction. The number of organ systems in failure 
was summed for the preweaning period.  
Process-level variables included RESTORE group assignment and the number of 
sedative medication classes administered (i.e., opioid, benzodiazepine, alpha-2-agonist, 
ketamine, barbiturate, propofol, and chloral hydrate). Compliance with sedation 
assessments during the pre-weaning period was a continuous variable based on daily 
assessment of a child’s level of sedation using the State Behavior Scale.5 This analysis 
averaged daily compliance over the preweaning period, yielding a percent compliance for 
each subject.  
Items drawn from the pre-randomization organizational assessments included: 
hospital accreditation status with the American Nurses Credentialing Center (i.e., Magnet 
Recognition® status) and availability of a professional advancement program for nurses; 
PICU characteristics, such as unit-type (i.e., open versus closed), bed capacity, budgeted 
census, and number of admissions in the preceding year; and staffing characteristics, such 
as number of attending physicians, fellows, and registered nurses, and typical nurse-to-
patient ratios.  
Power calculation: A total of 34 potential predictors variables at the patient-, 
process- and system-level were identified for evaluation in this secondary analysis (Table 
E1). Therefore, approximately 340 events were needed. Assuming an incidence rate of 
approximately 30% for IWS in the study population, logistic regression of the binary 
response variable (i.e., IWS versus no IWS) on continuous, normally distributed 
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explanatory variables with an inflated sample size of approximately 1160 observations 
was found to achieve 80% power at a 0.05 significance level to detect an odds ratio of 
1.7. The estimated sample size was inflated to account for intra-cluster correlations due to 
the cluster-randomized design of the parent study. Sample size calculations were based 
on a small effect size (R2 = 0.08) from previous studies6 to produce conservative 
estimates, and it was anticipated that the study would be adequately powered even if 
some patients were excluded. 
Model diagnostics: Preliminary model building was completed, and automated 
stepwise regression with bootstrapping was used to check manual variable selection. 
Related models were compared using Aikake information criterion (AIC) and sample-
size corrected Bayesian information criterion (BIC) values. These analyses were 
completed using Mplus version 7 (Muthén & Muthén, Los Angeles, CA). After 
determining the final model, model assumptions and fit were checked using c-statistics, 
receiver operating characteristic (ROC) and calibration curves. The robustness of the 
findings was further assessed using k-fold cross-validation for model calibration and 
bootstrapping procedures to obtain bias-adjusted confidence intervals.  
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Supplemental Table 
Table 4-5. Predictor variables of interest 
Variable Type Timing of Measurement 
Patient-Level  
Age Continuous Admission value by 
subject Gender  Binary  
Race/Ethnicity  Binary [Non-Hispanic 
White/ Minority] 
Pre-existing cognitive disability  Binary 
Pre-existing physical disability Binary 
Severity of illness (PRISM III-12 score) Continuous 
Meets organ dysfunction criteria Categorical Preweaning summary by 
subject Extracorporeal support required during 
hospitalization preweaning  
Binary 
Tolerance to opioids Binary 
Peak, total and cumulative [preweaning] 
opioid exposure and duration 
Continuous  
Peak, total and cumulative [preweaning] 
benzodiazepine exposure and duration 
Continuous 
Process-Level 
Number of classes of sedative agents  Categorical Preweaning summary by 
subject Sedation assessment compliance Continuous 
Inconsistent pattern of weaning Binary 
RESTORE intervention  Binary 
System-Level 
Nursing workload (NEMS score) Continuous Preweaning summary by 
subject 
Unit-based pharmacist participation in 
daily rounds 
Binary By PICU 
Total number of PICU beds Continuous 
Mean PICU daily census Continuous 
Annual PICU admissions Continuous 
Number of PICU attending physicians Continuous 
Number of PICU nurses Continuous 
Proportion of staffing with 1 nurse:1 
patient 
Continuous 
Proportion of BSN-prepared nurses Continuous 
Professional advancement program for 
nurses 
Binary  
ANCC Magnet Recognition Binary 
Medical management: Open PICU  Binary 
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CHAPTER 5  
DISCUSSION AND CONCLUSION 
 Sedation management in the pediatric intensive care unit (PICU) is a complex 
process that requires the consideration of many factors to proceed optimally; there are 
multiple decision points that could potentially set a patient on the path to experiencing 
iatrogenic withdrawal syndrome (IWS). Sedative medications elicit variable patient 
responses, so patients are prescribed medications at pharmacokinetically and 
pharmacodynamically appropriate doses to achieve the desired effects (Johnson et al., 
2012). Clinical practice has gradually incorporated routine evaluation of pain and level of 
sedation (Playfor et al., 2006), which has improved patient comfort during the critical 
phase of illness. To a lesser extent, clinicians are increasingly aware of the potential for 
medication tolerance, which is typically addressed by increasing sedative doses to 
maintain therapeutic effectiveness (Anand et al., 2010). This careful focus on patient 
comfort must be balanced against other clinical priorities during recovery, such as 
endotracheal extubation. The point at which concurrent ventilator and sedation weaning 
begins generates conflicting goals of preventing respiratory depression and promoting 
spontaneous breathing while avoiding patient discomfort (Brinker, 2004). Optimal 
sedation arguably requires a smooth transition from acute illness to recovery, especially 
when poorly executed sedation weaning leads to uncomfortable complications, like IWS, 
which are profoundly distressing for patients and families. Unfortunately, little attention 
has been paid to characterization of the crucial period of sedative weaning and the events 
that follow. This dissertation study contributed to current knowledge regarding pediatric 
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sedation management by exploring the relationship between weaning and IWS outcomes, 
and by identifying additional contributors to the development of IWS. 
Summary and Overall Goals 
 The three papers presented in this dissertation study collectively accomplished the 
following objectives: 1) exploring the available literature on iatrogenic withdrawal 
syndrome (IWS) to identify known and hypothesized risk factors for IWS in pediatric 
patients recovering from critical illness, 2) generating and characterizing patterns of 
sedation weaning to examine their association with the outcome of IWS, and 3) 
constructing a predictive model of patient risk for IWS to suggest improvements in future 
care of patients being weaned from sedation. The conceptual model created in the first 
paper (Chapter 2) elucidated relationships that were further explored in the remaining 
analyses (Chapters 3 and 4) and provided a framework for interpreting their findings. For 
example, tolerance and weaning were two identified concepts that were intricately related 
to IWS but which required more empirical evaluation. The description of usual clinical 
practice for sedative weaning in drug tolerant children (Chapter 3) tested operational 
definitions that performed well, warranting their inclusion in the exploratory modeling of 
IWS risk completed in Chapter 4. 
Major Findings: Tolerance 
 Physiologically, tolerance is an adaptive process whereby changes in receptor 
number and composition, uncoupling of secondary messenger systems, and increased 
release of various neuroactive substances are hypothesized to cause decreased therapeutic 
effectiveness of medications (Anand et al., 2010; Barr et al., 2011; Vinkers & Olivier, 
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2012). Tolerance is neither necessary nor sufficient for the development of physical 
dependence and subsequent IWS (Vinkers & Olivier, 2012), although tolerance and IWS 
may share certain predisposing factors, including sedative duration. They are distinct 
phenomena that occur during and after treatment, respectively, and have different 
implications for clinical management. Tolerance is undesirable since it interferes with the 
attainment of optimal sedation, and investigations of predictors for tolerance (Anand et 
al., 2013) may be valuable for increasing the efficiency of sedation practice. When 
managed through appropriate dose escalation in acute illness and gradual weaning during 
recovery, tolerance is not directly harmful to patients. It is only when tolerance leads to 
physical dependence and subsequent IWS that added patient discomfort, anxiety for 
families, and increased costs of care manifest (Franck et al., 1998; Johnson et al., 2012; 
Sorce, 2005). Thus, for the purposes of this investigation of risk factors for IWS, 
tolerance is only relevant in the subpopulation of patients for whom it develops prior to 
IWS.  
 Unfortunately, quantifying tolerance remains challenging. Since the exact cellular 
mechanisms underlying medication tolerance are still under investigation, there are no 
biological markers signaling its development. Providers have traditionally relied on dose 
escalation and decreased effectiveness of sedative medications as clinical indicators of 
tolerance (Anand et al., 2010). Opioid dose escalation is not specific to tolerance, as it 
could be related to the increased need for post-surgical analgesia or sub-optimal initial 
doses. The revised operational definition of tolerance that was used in the second and 
third papers accounted for this lack of specificity by comparing later opioid doses to the 
Day 2 dose, rather than the first 24 hours’ dose as in previous publications (Anand et al., 
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2013). Yet over 20% of subjects without IWS (based on WAT-1 scores) still met criteria 
for tolerance in both studies, further illustrating that tolerance may be insufficient to 
trigger physical dependence and IWS in the absence of other risk factors. This result may 
also be indicative of a continued lack of specificity in the revised definition of tolerance. 
More accurate clinically-based definitions of tolerance require a subjective assessment of 
the point at which adequate sedation was achieved in order to determine when therapeutic 
effectiveness starts to diminish, which may not be feasible for patients along varying 
illness trajectories and which poses problems for generalizability and reproducibility. 
These are all important considerations that may help explain why tolerance was not 
retained as a significant predictor in the final multivariable model of IWS risk. 
 In the conceptual model from Chapter 2, the various risk factors for IWS were 
classified as either tolerance- or non-tolerance-related. From a theoretical standpoint, it is 
still reasonable to consider tolerance as a potential contributor to IWS risk for certain 
patients, since tolerant patients appear to experience longer durations of sedative 
exposure. Alternatively, evaluating the sub-population of patients who develop tolerance 
but not physical dependence may prove to be advantageous, if protective factors could be 
identified that prevent the development of IWS. In either case, further work in this area 
may need to wait for more precise measures of tolerance to be developed, separating it 
from the other clinical influences driving dose escalation in the context of critical illness. 
Major Findings: Weaning 
 Sedative weaning has received limited attention in the pediatric literature, except 
in studies testing the use of pharmacologic therapies to facilitate faster weaning without 
precipitating IWS (Bowens et al., 2011; Jeffries, McGloin, Pitfield, & Carr, 2012; 
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Johnson et al., 2010; Meyer & Berens, 2001; Siddappa et al., 2003; Tobias, 2006). To 
date, published reports on sedation weaning have relied on quantifying dose reductions as 
percentages of the original dose (Ducharme et al., 2005), often assuming that weaning 
occurs as a linear decrease in dose over time at a rate determined by the healthcare 
provider. Only one recent descriptive study described daily opioid tapering that included 
increases in dose after the start of weaning, which occurred in 88% (n=22) of patients 
(Fisher et al., 2013). The portion of this dissertation study investigating patterns of 
weaning demonstrated that nearly half of patients experienced inconsistent patterns of 
weaning, which were associated with lower average percent drops in opioid dose and a 
higher incidence of IWS. Both prospective studies described in this dissertation further 
showed that the rate of dose reduction is not a key determinant of either weaning 
trajectory or development of IWS. 
 It was somewhat unexpected that predictors of inconsistent weaning patterns 
could not be identified from preweaning variables. However, on further scrutiny this 
difference in findings between the second and third papers – that is, that clinical variables 
may predict the outcome of IWS but not weaning patterns – highlights the fact that the 
etiology of IWS risk is multifactorial. These results also suggest that variations in 
sedative weaning are better explained by clinician or system factors than by inherent 
differences in severity of illness or sedative responsiveness in individual patients. 
Although additional work should prospectively examine this hypothesis, if confirmed it 
reinforces the need to critically reexamine the process in which sedation-related decisions 
are made in the PICU.  
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Major Findings: Patient-Level Risk Factors 
 The systematic review (Chapter 2) identified an area of disagreement in the 
current literature on patient-level risk factors for IWS: the evidence was inconsistent 
regarding the contribution of age to IWS risk, with some studies suggesting associations 
with either younger or older age. The results described in Chapter 4 provide evidence to 
resolve this question, since younger children had the highest incidence of IWS of the four 
age groups examined. The high rate of IWS in young infants was primarily interpreted in 
the context of developmental changes in the pharmacokinetics of sedative drugs; namely, 
that the CYP3A4 and UGT2B7 enzymes are differentially expressed and have low 
activity during the first days to weeks of life (de Wildt, de Hoog, Vinks, van der Giesen, 
& van den Anker, 2003; Knibbe et al., 2009; McRorie, Lynn, Nespeca, Opheim, & 
Slattery, 1992; Salem, Johnson, Abduljalil, Tucker, & Rostami-Hodjegan, 2014). Rates 
of drug metabolism and clearance change from birth to 6 or 12 months (Anderson & 
Larsson, 2011; Knibbe et al., 2009), depending on the individual patient’s physiology and 
the medication under examination (Kearns et al., 2003). 
 The lower mean daily opioid and benzodiazepine doses observed in patients under 
six months suggest that the ontogeny of drug metabolism in these patients was taken into 
account in dosing during the preweaning period. Since receiving lower doses of sedative 
medications still did not result in a lower incidence of IWS in this patient group, perhaps 
a greater awareness among clinicians of the potential effects of delayed clearance on the 
development of physical dependence is warranted. Specifically, daily dose reductions 
(Anand et al., 2010; Galinkin & Koh, 2014) may be misaligned with extended hepatic 
clearance times in young infants, resulting in dramatic changes in plasma serum 
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concentrations during weaning. More gradual weaning may be necessary in the youngest 
group of patients to prevent the development of IWS. There were no age-related 
differences in the patterns of weaning described in Chapter 3, which could mean that 
signs of IWS are not addressed with rescue medications as often in young infants. A 
simpler explanation is that young infants are weaned in a similar manner to older 
patients, suggesting an opportunity both to try more individualized sedation or weaning 
approaches in infants under six months and to improve the management of IWS 
symptoms as they occur in these patients.  
 Although the literature review identified several anecdotal reports of more 
frequent IWS in children with pre-existing disorders or hypoxemic brain injuries, it was 
surprising that the study in Chapter 4 was able to show a relationship between pre-
existing cognitive impairment and IWS. The Pediatric Cerebral Performance Category 
(PCPC) is a gross measure of cognitive impairment in children, which has been 
correlated with risk of mortality, PICU length of stay, discharge care needs and long-term 
developmental outcomes (Fiser et al., 2000; Fiser, 1992). However, PCPC scores have 
not been previously used to predict more short-term outcomes or complications that are 
contingent upon several aspects of clinical care. In the case of IWS, pre-existing 
cognitive impairment as a risk factor for IWS may be too granular to drive real changes 
in sedation management without further investigation. As described in Chapter 4, 
neurochemical differences in excitatory and inhibitory transmission may explain this 
finding, but additional pre-clinical work is needed to explore the pharmacodynamics of 
sedative medication activity in neurologically impaired brains.  
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 As a general observation, the use of sedative medications in children with 
cognitive and neurological impairments is relatively poorly characterized. For example, 
only recently have studies been published to counter the notion that children with Down’s 
syndrome have higher opioid requirements than other critically ill children (Valkenburg 
et al., 2012; Van Driest et al., 2013). This gap in the literature is problematic, given that 
up to a quarter of PICU patients may have pre-existing cognitive impairments (Graham, 
Dumas, O’Brien, & Burns, 2004) and that advances in medical care have led to 
increasing numbers of children with technological dependence and/or chronic conditions 
with neurologic components (Namachivayam et al., 2010; Odetola, Gebremariam, & 
Davis, 2010). Up to this point, evidence has shown that sedative medications are effective 
for use in children with cognitive impairments (Buck & Willson, 2008; Kilbaugh, Friess, 
Raghupathi, & Huh, 2010; Valkenburg, van Dijk, de Klein, van den Anker, & Tibboel, 
2010), but the results of this study suggest that more careful evaluation of the safety and 
long-term effects of these medications may be needed in this population. 
 There is a robust body of evidence for sedative dose and duration as risk factors 
for IWS (Chapter 2). The results of this dissertation unanimously confirmed the 
importance of considering both variables in evaluating a patient’s probable course of 
weaning and predicting risk for IWS; therefore, the inclusion of both a dose and duration 
variable in the predictive model (Chapter 4) gives some measure of face validity to the 
findings. In addition, though it is intuitive for clinicians that patients receiving higher 
preweaning doses and/or longer durations of sedation have more difficulty with weaning, 
the analysis presented in Chapter 3 was the first direct evaluation of the contributions of 
preweaning sedative dose and duration to weaning outcomes. A problem in some older 
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studies of IWS (Bergman et al., 1991; Dominguez et al., 2003; Fonsmark et al., 1999; 
Franck et al., 1998; French & Nocera, 1994; Hughes et al., 1994; Katz et al., 1994) that 
was identified and addressed in these dissertation studies, is the inclusion of medication 
doses received after the start of weaning in quantifying the relationship between sedative 
exposure and IWS. A few recent investigations have differentiated between pre- and 
post-weaning doses and acknowledged the correlations among medication variables 
(Franck et al., 2008; Franck et al., 2012). However, by highlighting this gap in previous 
approaches, these methods and findings add a much-needed level of conceptual clarity to 
the study of contributors to IWS in critically ill children. 
Major Findings: Process-Level Risk Factors 
 The only process-level factor found to be a significant predictor of IWS was 
number of sedative agents used in the preweaning period: subjects who received three or 
more classes of sedative medications were more likely to experience IWS. The same 
variable did not achieve statistical significance in the study of weaning patterns, though 
inconsistently weaned patients did appear to receive more sedative agents in the 
preweaning period, and receipt of additional sedative classes occurred more frequently 
among inconsistently weaned patients during weaning (p<0.001). Taken together, these 
findings highlight the difficulty of interpreting the relationship between multi-drug 
therapy and IWS: prescription of additional sedative medications during weaning is most 
indicative of attempts to manage emergent signs and symptoms of IWS, but in the 
preweaning period the clinical rationale for this approach requires some speculation. It is 
likely that at least some of the children who received three or more sedative agents were 
difficult to sedate with traditional opioid and benzodiazepine medications. There is an 
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incomplete understanding of the reasons for pharmacodynamic variation in sedative 
response in critically ill children (Johnson et al., 2012; Vet, de Hoog, Tibboel, & de 
Wildt, 2011), and even less about how it might translate into a predisposition for physical 
dependence or difficulties with weaning. This finding is particularly perplexing to explain 
given that the direction of effect was opposite that in a previously published model of 
IWS risk (Ista et al., 2013), which reported seemingly protective effects for one or two 
additional sedative medications (respectively, OR 0.11, 95% CI 0.28-0.42, p=0.001; OR 
0.19, 95% CI 0.05-0.76, p=0.02). However, that study did not clearly describe whether 
additional sedatives were administered solely in the preweaning phase and did not 
distinguish between medications treating signs and symptoms of withdrawal (i.e., 
clonidine, ketamine, fentanyl) versus other sedatives (i.e., propofol). Their findings may 
reflect more proactive treatment of mild symptoms of IWS during weaning, while ours 
specifically address sedative needs in the preweaning period.  
 It is interesting that RESTORE group assignment did not appear to influence the 
outcome of IWS. The primary study found that patients in the intervention group had 
fewer days of opioid exposure, received fewer sedative classes (including less 
methadone), and, based on sedation assessments, were more often considered to be 
awake and calm during mechanical ventilation than subjects in the control group (Curley 
et al., 2015). Nevertheless, IWS rates reported in the primary paper were 68% in both 
study groups. This result may be a reflection of the complex nature of IWS, wherein 
other determinants of a patient’s risk could offset the beneficial effects of lower 
medication doses. For example, more patients less than two years of age were enrolled in 
the intervention group, and their higher observed rates of IWS might have obscured the 
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potentially preventive effects of the sedation protocol on the incidence of IWS. 
Compliance with WAT-1 assessments was also higher in the intervention group, raising 
the distinct possibility that IWS was more likely to be identified in those patients. Thus, 
the results in Chapter 4 cannot be interpreted as a statement on the effectiveness of 
standardized sedation protocols in preventing IWS, and it is recommended that additional 
studies using IWS as the primary outcome be developed to more thoroughly evaluate this 
relationship.   
Major Findings: System-Level Risk Factors 
 A novel contribution of this dissertation was the evaluation of the effects of the 
healthcare system on the outcome of IWS. As a phenomenon defined primarily by its 
clinical signs and symptoms, IWS is typically described at the patient level. Many 
previous investigations have been limited to single centers and could not comment on 
variations across sites. However, certain authors noted process challenges (Carnevale & 
Ducharme, 1997; Ducharme et al., 2005; Jin et al., 2007) which suggested elements of 
sedation management that were common across institutions. The literature review 
(Chapter 2) demonstrated that studies of IWS up to this point have frequently lacked 
contextualization based on the unique circumstances in which sedation occurs, namely, 
within complex health systems.  
 Systems factors were not directly evaluated in the second study, but using 
baseline data from the RESTORE trial yielded findings that were potentially driven by 
practice norms at each of the participating PICUs. Unmeasured influences on inconsistent 
weaning may have existed, such as periods of high unit census and hospital policies 
prohibiting use of continuous infusions on general floor units (Tobias, 2000). Clinicians 
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sometimes perceive that gradual tapering of sedatives will delay extubation or discharge 
from the PICU to the floor (Tobias, 1996, 1999), despite the fact that studies of 
standardized sedation protocols including weaning (Deeter et al., 2011; Jin et al., 2007; 
Keogh, Long, & Horn, 2015) have shown decreased or unchanged lengths of stay. 
However, there have been no systematic investigations of the precise relationship 
between sedative weaning as the primary intervention and time to extubation or 
discharge, besides a study showing no difference in the success rate of methadone-
facilitated weaning using a 5 or 10 day protocol (Bowens et al., 2011). Nevertheless, over 
the course of the RESTORE trial, clinicians expressed a declining inclination to wean 
sedative medications (Best, Wypij, & Curley, 2014), presumably in favor of rapid 
discontinuation of continuous infusions. Thus, if faced with a shortage of PICU beds and 
external pressure to move patients to the floor, patients who otherwise would be weaned 
more slowly might be pushed into the process prematurely. This explanation is purely 
speculative, and may be countered by the observation that percent decreases in opioid 
dose were lower among inconsistently weaned patients.   
 In the final paper, both high nursing workload and greater proportions of high 
nurse to patient staffing ratios were identified as contributors to IWS risk. The discussion 
in Chapter 4 thoroughly explored the potential implications of these findings, which 
unfortunately offer limited room for interpretation because of the lack of patient-level 
data. Nurse to patient staffing ratios are often used in health policy research as an indirect 
indicator of nursing workload (Carayon & Gürses, 2005; Cimiotti, Barton, Chavanu 
Gorman, Sloane, & Aiken, 2014; Tubbs-Cooley et al., 2013), and higher levels of nurse 
staffing are typically associated with improved quality of care and better patient 
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outcomes (Numata et al., 2006). Therefore, the direction of the effect of staffing ratios on 
IWS incidence contradicted the finding that higher nursing workload (based on NEMS 
scores) was a risk factor for IWS. Although the most logical explanation is an effect of 
ascertainment bias, there may be other relevant but unmeasured influences at sites with 
higher proportions of one-to-one nurse staffing that do exert a true effect on increased 
risk for IWS, such as work environment (Kelly, Kutney-Lee, Lake, & Aiken, 2013; 
McHugh et al., 2013) or nursing education (Aiken et al., 2003; Egerod, 2002; Guttormson 
et al., 2010; Kutney-Lee et al., 2013). 
 The fact that unit size and number of annual admissions were not found to have 
significant relationships with IWS is not unusual. One systematic review of 
organizational research in healthcare reported that more than 45% of studies investigating 
the effects of the system or structure on patient outcomes yielded non-significant findings 
(Hearld et al., 2008). This observation stems in part from the complexity of clinical 
patient care, especially in the PICU, where a diverse set of process and system influences 
can operate to varying degrees to either directly or indirectly influence patient-level 
outcomes. However, previous pediatric studies have demonstrated associations between 
PICU volume and patient outcomes (Tilford, Simpson, Green, Lensing, & Fiser, 2000). 
The final study (Chapter 4) attempted to address this challenge by adjusting for factors at 
the patient, process and system levels. It is also possible that the reported proportion of 
high nurse-to-patient staffing ratios at each site was indirectly related to unit volume or 
census, and therefore including the staffing variable accounted for those effects. Overall, 
a few system-level variables did reach statistical significance in this analysis. Further 
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exploration of systems influences on IWS might confirm these results or identify 
additional system-level contributors. 
Limitations 
 The limitations of this dissertation include the use of an unvalidated conceptual 
model, difficulty in operationally defining and measuring certain variables of interest, 
and potential biases in the available study sample. The conceptual model developed in the 
first study was derived through a qualitative synthesis of the available literature on IWS 
risk; it is possible that another author provided with the same data might have reached 
different conclusions. The remaining studies in this dissertation used this framework to 
guide variable selection, which may have led to erroneous assumptions about the 
relationships between variables. However, the final study successfully identified 
predictor variables at each level of the model, lending some support to the initial 
hypothesis that influences outside of the patient ought to be considered. 
 As in previous studies of sedation management in the PICU, these analyses were 
unable to differentiate between the effects of opioid and benzodiazepine exposure on 
either weaning patterns or IWS risk. Only two studies to date have examined both opioid 
and benzodiazepine patterns of weaning together (Ducharme et al., 2005; Ista et al., 
2013), in part due to the difficulty of defining the start of weaning for each individual 
medication. Rather than replicating these approaches, this dissertation defined the start of 
weaning relative to opioid administration, which has been more thoroughly described as a 
contributor to IWS in children recovering from critical illness. This design decision may 
have neglected important information that could have been gleaned from considering 
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both medications together, especially since less is known about physical dependence on 
benzodiazepines and appropriate weaning approaches. 
 Inconsistent patterns of weaning were more frequently observed among patients 
with IWS compared to non-IWS patients, but ultimately this association was not explored 
further in the final study (Chapter 4), in part because of the difficulty in demonstrating 
causal relationships in this study design. Specifically, inconsistent weaning could not be 
definitively identified as the cause of higher observed WAT-1 scores in either of the 
studies including weaning pattern. Future prospective analyses could investigate the 
timing of onset of IWS symptoms relative to the start of inconsistent weaning. 
 Compliance with standardized assessments was less than perfect in the studies 
that relied upon baseline (Chapter 3) and post-randomization data (Chapter 4), making 
interpretation of the results more challenging. Difficulties with compliance have been 
frequently reported in the literature on sedation assessment: a recent survey noted that 
although 70% of respondents worked in PICUs implementing standardized sedation 
assessment tools, only 42% of clinicians actually used them to guide sedation 
management (Kudchadkar, Yaster, & Punjabi, 2014). Given the recent development of 
both the WAT-1 (Franck et al., 2008; Franck et al., 2012) and its Dutch counterpart, the 
SOS (Ista et al., 2008; Ista et al., 2013), very little research has evaluated compliance 
with withdrawal assessment, particularly over the course of a five year clinical trial. 
However, published findings indicate inconsistent use in clinical practice (Jeffries et al., 
2012; Keogh et al., 2015). It is likely that non-compliance with sedation and withdrawal 
assessments is at least in part related to clinician biases: patients who were perceived to 
have a “smoother” sedation course may have been less likely to be assessed, if they were 
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considered by clinicians to be at lower risk for IWS than patients with more complex 
sedation needs. However, there was no way to directly evaluate the effects of clinician 
attitudes and beliefs in the context of this secondary analysis. 
 Finally, as has been stated previously, the association between system-level 
variables and IWS outcome could not be adequately assessed in the absence of 
individually collected data for each subject. As a secondary analysis, the self-reported 
site-level organizational assessment data were the only available system-level variables. 
There was variation over the course of the study in terms of what data was available at 
each site, and many sites simply did not have processes in place for obtaining the 
requested data, particularly for nursing variables. As a result, there was more missing 
data in the organizational dataset than in the larger study.  
Future Directions 
 The most obvious contribution of this dissertation work is to suggest additional 
caution in the approach to sedation management and weaning in certain groups of 
critically ill children. Patients under six months of age may require an alternative strategy 
of sedation titration to avoid doses that induce physical dependence and possibly different 
weaning approaches to avert symptoms of IWS. However, weaning alone may be 
ineffective as an approach to preventing IWS. Sedation in children with pre-existing 
cognitive impairments should also be managed conservatively. The design of this 
dissertation study precludes any mechanistic explanation for why these patients may have 
experienced more IWS despite similar sedative doses and duration of exposure. It is 
reasonable to hypothesize that these patients have altered responses to sedative 
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medications due to pre-existing neurochemical differences, but additional pre-clinical and 
clinical studies are needed. 
 Although this study was originally intended to investigate the relationship 
between race/ethnicity and risk for IWS, this was not done for several practical reasons. 
Documentation of race/ethnicity in the RESTORE trial was based upon the research 
personnel’s impressions of the patient on admission and was not self-reported, raising 
concerns about potential misclassification. The theoretical basis for including 
race/ethnicity as a potential risk factor for IWS could not be substantiated; it is unknown 
whether the underlying distribution of polymorphisms in genes responsible for opioid 
and/or benzodiazepine metabolism would be reproduced by the available codings of 
race/ethnicity without analysis of biological data from the sampled RESTORE subjects. 
Adopting race/ethnicity as proxies for genetic differences in drug metabolism is no longer 
a recommended approach in pharmacogenetic research (Lee, 2009). Therefore, future 
studies including patient genotypes for potentially contributory genes – such as single 
nucleotide polymorphisms in the mu opioid receptor (OPRM1), ATP binding cassette 
transporters (ABCB1), and the cytochrome P450 family (Anand et al., 2010) – should 
examine direct relationships with the outcome of IWS. Some of this work is already in 
progress, with promising results (Beer et al., 2013). 
 This study of risk factors for IWS in pediatric patients recovering from critical 
illness has provided valuable insights into current processes of sedation management in 
the PICU, but it also raises a host of new questions. For example, despite efforts to 
explore the system context of sedation management in the PICU, little is known about the 
physical environment in which the children in these analyses were receiving sedation 
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therapy and recovering from critical illness. Although gradual weaning remains the most 
promising approach to reducing the incidence of IWS, there is increasing interest in 
reducing noxious environmental stimuli as a means to decreasing sedative needs in 
critically ill children. Families could be engaged in helping to use non-pharmacologic 
measures for reducing agitation, such as music therapy, massage, and other 
complementary therapies (Brinker, 2004; Stephen Playfor et al., 2006). However, the 
success of such interventions is contingent upon the unique organizational dynamics of 
the PICU (Burns, 2012; Thomas & Dhanani, 2010). 
 If the system-level variables identified in this study are examined prospectively 
with patient-level data and similar relationships are observed, it may be advisable to 
examine strategies for increasing resources and better allocating nursing assignments for 
high-risk patients. Recent studies have suggested that inadequate nursing resources are 
associated with reduced surveillance for potential changes in patient condition (Cimiotti 
et al., 2014) and more instances of “missed care” (Ball, Murrells, Rafferty, Morrow, & 
Griffiths, 2014). It would be interesting to probe the process of how nurses allocate their 
time to sedation-related versus other care activities, how sedation assessment and 
weaning are prioritized, and what additional resources could help support optimal 
practice, thereby reducing nursing workload. Such an investigation could incorporate an 
assessment of the quality of interprofessional dialogue surrounding sedation; relying on 
Magnet status as an indicator of the quality of work environments may have been too 
granular an approach in this study, and previous findings strongly suggest that 
interprofessional communication regarding sedation goals influences nurses’ attitudes 
toward weaning and IWS assessment (Suddaby & Josephson, 2013). 
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Conclusion  
This dissertation has explored and advanced knowledge regarding iatrogenic 
withdrawal syndrome in children recovering from critical illness and weaning from 
sedative medications. The conceptual model proposed in the first paper provided a 
framework for designing and interpreting the remaining two studies, although external 
validation is needed. In addition to critically examining the role of tolerance in 
precipitating IWS, this dissertation has elucidated the relationship between weaning and 
IWS, and provided a reproducible methodology to guide future research. Most 
importantly, both classic and novel risk factors together contributed to a predictive model 
of IWS risk that adjusted for variables at the levels of the patient, process and system.	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APPENDICES 
Appendix 1. Withdrawal Assessment Tool-version 1 (WAT-1) 
 
 
Reference: Franck LS, Scoppettuolo LA, Wypij D, Curley MAQ. Validity and generalizability of the 
Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric 
patients. Pain. 2012;153(1):142–148.  
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